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Norsk sammendrag av avhandling: 
ADHD hos voksne; samsykelighet og behandling med sentralstimulerende legemidler 
ADHD er en tilstand som oppstår i barndommen og preges av hyperaktivitet, impulsivitet og 
oppmerksomhetssvikt. Symptomene på ADHD vedvarer inn i voksen alder hos mange 
pasienter, og er forbundet med funksjonssvikt på områder som utdannelse og arbeidsliv. 
Forekomst av andre psykiske lidelser samtidig (samsykelighet) er stor gjennom hele livsløpet. 
Sentralstimulerende legemidler (SSL) er godt dokumentert behandling av symptomene ved 
ADHD. Til tross for god symptomatisk effekt slutter mange pasienter tidlig med 
behandlingen, og mye er uavklart når det gjelder hvordan SSL behandling fungerer i vanlig 
klinisk praksis hos voksne.  
Vi ønsket å beskrive forekomst av samsykelighet og funksjonssvikt hos voksne pasienter med 
ADHD. Videre ønsket vi å se på behandlingsforløp og identifisere variabler som predikerte 
behandlingsvarighet > 3 år. Det tredje målet med studien var å undersøke forekomsten av 
rusmisbruk i løpet av behandlingsforløpet og identifisere variabler knyttet til eventuelt 
misbruk. Vi ønsket også å identifisere kliniske og behandlingsmessige variabler relatert til 
yrkesmessig fungering i voksen alder. 
Dette er en retrospektiv, naturalistisk studie på 3 utvalg av voksne pasienter med diagnosen 
ADHD. Den primære utredningen av pasientene ble gjort i henhold til prosedyrer bestemt av 
de Sakkyndige team for hyperkinetisk forstyrrelse i perioden 1997-2005. Hovedmengden av 
data til studien ble retrospektivt hentet fra den psykiatriske journalen. I Paper IV brukte vi i 
tillegg et spørreskjema.  
Vi fant at voksne med ADHD hadde lavere utdanningsnivå og yrkesdeltagelse enn den 
generelle befolkningen. Mange pasienter hadde samsykelighet som rusmisbruk og 
personlighetsforstyrrelse. Til tross for de høye nivåene av samsykelighet og funksjonssvikt 
fikk de fleste pasientene behandling med SSL i lang tid (median varighet var 33 måneder). 
Behandlingsvarighet mer enn 3 år ble positivt predikert av om pasienten brukte 
langtidsvirkende SSL, og negativt predikert av om pasienten hadde personlighetsforstyrrelse. 
Hos pasienter uten tidligere rusmisbruk fant vi at behandling med SSL ikke førte til 
rusmisbruk. Pasienter som tidligere hadde hatt rusmisbruk hadde ikke høyere tilbakefall enn i 
grupper av voksne pasienter med rusmisbruk alene. Høy alder ved første SSL behandling og 
høyere grad av oppmerksomhetssvikt var assosiert med redusert yrkesdeltagelse i voksen 
alder. 
Avhandlingen understreker det høye nivået av samsykelighet og funksjonssvikt ved ADHD 
hos voksne. Det viser seg allikevel mulig å behandle pasientene med SSL over lang tid, men 
det må undersøkes nærmere hvordan behandlingen skal gjennomføres hos pasienter med stor 
samsykelighet. En lengre periode med rusfrihet før SSL behandling kan redusere risiko for 
tilbakefall, men dette må undersøkes med kontrollerte studier. Studien antyder at tidlig 
behandling av ADHD er relatert til bedre yrkesmessig fungering i voksen alder, men i likhet 
med andre naturalistiske studier er det store metodologiske begrensninger. Vitenskapelig mer 
robuste studier bør gjøres for å undersøke effekten av SSL behandling av barn og unge på 
funksjonsnivå og samsykelighet i voksen alder.
 
Institutt:   Institutt for nevromedisin 
Veiledere:  Professor Kirsten Rasmussen, professor Hans Morten Nordahl, 
førsteamanuensis Arne Vaaler 
Finansieringskilder:  Samarbeidsorganet mellom Helse Midt-Norge RHF og NTNU,  
Sykehuset Levanger, Psykiatrisk klinikk,  
og St. Olavs hospital, avdeling Østmarka 
Navn kandidat:  Terje Torgersen 
3 
 
Table of Contents 
Acknowledgement          5 
Summary           7 
List of publications          11 
List of abbreviations          12 
1. INTRODUCTION         13
1.1 Attention-deficit/hyperactivity disorder     13 
1.2 Persistence of ADHD into adulthood     15 
1.3 Comorbidity in adult ADHD       16 
1.3.1 Comorbid Substance Use Disorders     17 
1.3.2 Comorbid Antisocial personality disorder    19 
1.4 Functional impairment in adult ADHD     20 
1.5 Central Stimulant treatment of ADHD in adults    20 
1.5.1 Central Stimulants       21 
1.5.2 Effectiveness versus efficacy      23 
     2. THE PRESENT THESIS        23 
2.1 Research questions        25 
 2.2 Materials and methods       25 
  2.2.1 Patients        26 
2.2.1.1 Recruitment of patients to the present studies  26 
2.2.1.2 Diagnostic assessment     27 
2.2.2 Measures        28
2.2.2.1 Sociodemographic variables     28 
2.2.2.2 Comorbidity       29 
 2.2.2.3 Prevalence of SUD during CS treatment   29 
   2.2.2.4 Duration of abstinence from SUD    30 
   2.2.2.5 CS treatment variables     30 
 
  2.2.2.6 Self-Report Questionnaire     31 
 
2.2.3 Procedures         31 
4 
 
 2.3 Statistics         32 
2.4 Ethics          32 
     3. RESULTS          33
3.1 Paper I          33 
 3.2 Paper II         34 
 3.3 Paper III         36 
 3.4 Paper IV         37 
     4.  DISCUSSION         38
4.1 Methodological issues       38 
4.1.1 Patients        38 
4.1.2 Procedures        40 
4.2 Discussion on the main findings      42 
  4.2.1 Comorbidity        42 
4.2.2 Functional impairment      45 
4.2.3 Variables predicting long-term (> 3 years) CS treatment  47 
4.2.4 Prevalence of SUD during long-term CS treatment    51 
4.2.5 Variables predicting relapse of SUD during CS treatment  53 
4.2.6 Variables predicting occupational outcome in adult ADHD 53 
      5.  CONCLUSIONS         55
      6.  FUTURE PERSPECTIVES       56 
      7. REFERENCES         58
      8.  PAPERS I-IV 
      9. ATTACHMENTS I-IV 
 
 
 
 
5 
 
Acknowledgements  
The work with the present thesis started in 2004 when I was working as a staff 
psychiatrist at Sykehuset Levanger, Department of Psychiatry. Dr. Marit Bjartveit was a very 
enthusiastic and supportive Head of the Department, and created an environment in which 
research was both encouraged and desired. The combination of this positive attitude towards 
research, and my meeting with the increasing number of adult patients with ADHD at the 
clinic, inspired me to start clinical research related to this relatively new group of patients in 
adult psychiatry. At this time I also met Professor Kirsten Rasmussen at NTNU, Department 
of Psychology. She was probably the first to do clinical research on adult ADHD in Norway, 
and accepted to be my main supervisor. Without her warm, encouraging support and patience 
this project would never have come to an end. 
My good friend and colleague Bjørn Gjervan has been an invaluable partner all these 
years. We have been working together and have been involved in each other’s PhD projects. 
We have shared disappointments and hardship, but also the small victories and the joy of learning to 
be researchers. The last year our research has resulted in several published papers on adult ADHD and 
we have started a new ADHD research project.    
Bjørn; we said we could do it, and we did it!  
The first years of the study the research was done along with my clinical work at 
Sykehuset Levanger, Department of Psychiatry. The present Head of Department Hilde 
Ranheim and supervising physician Nils Håvard Dahl has always been supporting and 
contributed to the creation of clinical psychiatric research at the Department of Psychiatry. I 
am also very grateful to all my former colleagues at the hospital in Levanger for the creation 
of a stimulating, fun and professional work environment. My second supervisor professor Hans 
Morten Nordahl has been an important contributor throughout the project. 
In 2006 I received a scholarship from the Liaison Committee between the Central Norway 
Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), 
and this funding has been essential for the completion of the project. 
During the research project I have received support from the research environment at St. 
Olav’s hospital, Department of Østmarka, and AFFU (Avdeling For Forskning og Utvikling) in 
two periods. Professor Olav Linaker provided me an office in a two year period when I was 
6 
 
commuting between my clinical job at Sykehuset Levanger and my home in Trondheim, and 
invited me to join the research environment at AFFU.  
Two years ago I started a new job at an acute psychiatric ward at Department of 
Østmarka. Head of Department Pål Sandvik and leader of the acute wards Knut Langsrud has 
been very supportive and made it possible for me to continue and complete my PhD project. 
Professor Gunnar Morken at AFFU has also been helpful in the process of publishing my 
results the last two years. Associate professor and good colleague Arne Vaaler has been a 
main contributor and my third supervisor the last year. His ability to see what is essential and 
his enthusiasm for research has been invaluable for me in the final stage of the PhD project.  
I am very thankful to all the patients who participated in these studies, and have a deep 
admiration for their struggle to overcome their health problems. 
My wife Inger Lise is the most important person in my life, and without her love and 
care I could never have finished the project. You are simply the best! I am also grateful to my 
children Isak, Oskar and Line, and my “bonus” children Mats and Merete, for what they have 
learned me about life. 
 
Trondheim, November of 2012 
 
Terje Torgersen 
 
 
 
 
 
 
 
7 
 
 
Summary 
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental 
condition of childhood onset characterised by hyperactivity, impulsivity and attention deficit. 
The condition persists into adulthood in a significant number of patients, and is clinically 
heterogeneous in terms of symptoms, comorbidity, functional impairment and clinical course. 
There is a considerable presence of comorbid psychiatric disorders throughout the lifespan. 
ADHD in adults is associated with poor functional outcome in important life domains like 
educational and occupational achievement. Research indicates that especially substance use 
disorders (SUD) and antisocial personality disorder (ASPD) are linked to adult ADHD. 
Central stimulant (CS) drugs are considered to be the cornerstone of pharmacological 
treatment in ADHD. Several clinically important effectiveness variables were understudied 
when the present studies started; like continuity of CS treatment in ordinary clinical practice, 
predictors for continuity and reasons for discontinuation of CS treatment, and the impact of 
comorbid disorders on aspects of CS treatment. 
Objectives: The first main objective was to describe psychiatric comorbidity and functional 
impairment in 3 samples of clinical adult ADHD patients. The second objective was to to 
investigate CS treatment in a sample of adult ADHD and identify variables predicting long-
term (> 3 years) CS treatment. The third objective was to investigate the prevalence of SUD 
during long-term CS treatment in a sample of adult ADHD and identify variables associated 
with SUD during treatment, and the fourth was to identify variables predicting occupational 
outcome in adult ADHD.  
Methods: The present study is based on a retrospective, naturalistic design of 3 samples of 
adults diagnosed with ADHD in North-Trøndelag County in the period 1997 to 2009.  The 
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primary assessment of the patients was done according to procedures published by Expert 
Committees of Hyperkinetic Disorders/ADHD, as part of ordinary hospital routines. In a 
second step a report with all information gathered in the first step was sent to the Expert 
Committee of Hyperkinetic Disorders/ADHD for a definitive recommendation. The majority 
of data for the present study was retrospectively collected from the medical records by an 
experienced psychiatrist (the author). Paper IV additionally includes a cross-sectional 
questionnaire. The main measures were sociodemographic variables, baseline psychiatric 
comorbidity and the prevalence of SUD during long-term CS treatment, duration of 
abstinence from SUD before CS treatment started, and several CS treatment variables.   
Results: We found that Norwegian adults with ADHD had far lower levels of education and 
employment compared to the general population, and the patients had high levels of 
psychiatric comorbidity like SUD and ASPD. Despite the high levels of comorbidity and 
functional impairment most adults with ADHD received CS treatment for several years (mean 
duration was 33 months). Treatment duration for more than 3 years was predicted positively 
by the use of extended release (ER) formulations of methylphenidate (MPH), and negatively 
by comorbid ASPD. In adult ADHD patients without previous comorbid SUD we found that 
CS treatment did not precipitate new onset of SUD. In patients with previous SUD the relapse 
rate during CS treatment was not higher than in adult patients with SUD alone. We also found 
that later age of first CS treatment and higher inattentiveness ratings were associated with 
lower level of employment in adulthood. 
Conclusions: The present thesis emphasizes the high rates of comorbidity between adult 
ADHD and other psychiatric disorders like SUD and ASPD. In addition to a further emphasis 
on the impact of comorbidity on the course of ADHD future research should explore the 
functional impairment following ADHD in all ages, and identify treatment which is capable 
of reducing impairment. Further research should also focus on the treatment providing 
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systems and investigate factors that could enhance CS treatment effectiveness such as 
compliance. A longer period of abstinence from SUD before CS treatment may reduce the 
risk for relapse. However, trial derived evidence is lacking and it needs to be examined in a 
study with a prospective, controlled design. Early treatment of ADHD is shown in the present 
and some other long-term studies to be related to better adult functioning. However, most 
long-term studies are open-label extensions or naturalistic studies, with several 
methodological limitations. Efforts should be made to initiate larger, scientifically more 
stringent and multisite naturalistic studies to investigate the impact of different treatments on 
adult functional outcomes. 
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1. Introduction 
1.1 Attention-deficit/hyperactivity disorder 
Attention Deficit/Hyperactivity Disorder (ADHD) is a heterogeneous 
neurodevelopmental condition of childhood onset characterised by hyperactivity, impulsivity 
and attention deficit. The symptoms present in ADHD are found in varying degrees in the 
general population, and only those who have symptoms to an extreme degree and a functional 
impairment due to symptoms will fulfil the criteria for the diagnosis. ADHD is recognized as 
a valid disorder in children and adolescents, and during the last couple of decades also in 
adults (Clarke et al. 2005;Kooij et al. 2005). Still, the validity of the diagnosis in adults is 
disputed (Asherson et al. 2010;Matte et al. 2012;Moncrieff and Timimi 2010). A major 
problem is the lack of diagnostic criteria specific for adults, and the use of criteria developed 
for children when assessing adult patients (Matte et al. 2012).  
ADHD is a designation under the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, (DSM-IV) (American Psychiatric Association 1994). It differs in 
some aspects from the term Hyperkinetic Disorder (HD) according to the official diagnostic 
system in Norway; International Classification of Diseases, 10th revision (ICD-10) (World 
Health Organization 1992). The need for standardization between countries in research and 
clinical practice has led to an adaptation to the DSM-IV criteria worldwide, including 
Norway. In conjunction with the upcoming revision of the DSM-IV in 2013 major changes in 
the diagnostic criteria are discussed, like removing the three ADHD subtypes, changing the 
age of onset from 7 to 12 years, and fewer symptoms required for a diagnosis of adult ADHD 
(American Psychiatric Association 2012).
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 According to DSM-IV ADHD is divided into 3 subtypes; ADHD predominantly 
inattentive type, ADHD predominantly hyperactive-impulsive type and ADHD combined 
type. Patients with 6 or more out of 9 hyperactivity/impulsivity symptoms and 6 or more out 
of 9 inattention symptoms, will be classified as ADHD combined type. This is the most 
common subtype (Lahey et al. 1994;Wilens et al. 2009;Woo and Rey 2005) and the subtype 
mostly related to a unfavourable clinical outcome (Sobanski et al. 2008;Sprafkin et al. 
2007;Wilens et al. 2009). The ICD-10 diagnosis HD is almost equal to ADHD combined type, 
but requires 6 out of 9 inattention symptoms, 3 out of 5 hyperactive symptoms and 1 out of 4 
impulsive symptoms. Another difference between the diagnostic systems is that ICD-10 more 
strictly rules out ADHD if other psychiatric disorders are present at the same time. 
The ADHD inattentive subtype requires 6 or more out of 9 inattention symptoms. 
Fulfilling the criteria for this subtype is basically not sufficient for the ICD-10 diagnosis HD. 
The Norwegian Health Authorities introduced in 1997 an adaptation to the DSM-IV criteria, 
allowing the ADHD inattentive subtype as sufficient for the diagnosis F90.0 HD. Resent 
research indicates that the DSM-IV ADHD subtypes do not identify discrete subgroups with 
sufficient long-term stability to justify the classification of distinct forms of the disorder, and 
that empirical support is stronger for an alternative model that would replace the subtypes 
with dimensional modifiers that reflect the number of inattention and hyperactivity-
impulsivity symptoms at the time of assessment (Willcutt et al. 2012).  
The disorder is clinically heterogeneous in terms of symptoms, comorbidity and 
clinical course (Thapar et al. 2007). Despite increased research on ADHD in recent years 
there is still uncertainty when it comes to aetiology and genetics (Thapar et al. 2007). ADHD 
may not be classified as a categorical diagnosis with distinction between healthy and diseased 
individuals (Willcutt et al. 2012;Witkiewitz et al. 2012). Many patients with other mental 
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disorders have symptoms overlapping with ADHD, which can make a reliable differentiation 
between diagnoses difficult (Goodman and Thase 2009;Montano and Weisler 2011).  
The prevalence of ADHD world-wide is estimated to be 5.3% in children and 
adolescents (Polanczyk et al. 2007). In a World Health Organization survey of Europe, the 
Americas and the Middle East the estimates of DSM-IV ADHD prevalence in adults averaged 
3.4% (range 1.2-7.3 %), with lower prevalence in lower income countries (1.9%) compared 
with higher-income countries (4.2%) (Fayyad et al. 2007).  
 
1.2 Persistence of ADHD into adulthood 
Research indicates that the disorder persists into adulthood in 30-60% of the cases 
(Mannuzza et al. 1991;Polanczyk and Rohde 2007), but studies have showed that the 
estimates rely heavily on the definition of persistence (Faraone et al. 2006a). The lack of 
specific diagnostic criteria for the disorder in adults contributes to the uncertainty in 
persistence rate (McGough and Barkley 2004). Studies have shown that factors like ADHD 
symptom severity, functional impairment and psychiatric comorbidity are associated with 
persistence of ADHD into adulthood (Kessler et al. 2005c;Lara et al. 2009;Mick et al. 2010). 
Data suggest that among the core symptoms of ADHD the symptoms of inattention persist in 
a larger degree than hyperactivity and impulsivity (Biederman et al. 2000;Wilens et al. 2009). 
Clinically important attentional symptoms in adult ADHD may be poor attention and 
concentration, distractibility, frequent shifting of activities and forgetfulness (Wilens et al. 
2009). Associated impairments in adult ADHD are executive function deficits like problems 
with processing of information, organization and time management (Barkley 1997). Another 
associated feature of adult ADHD is emotional dysregulation, characterized by mood 
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instability, emotional over-reactivity, hot temper and irritability (Barkley and Fischer 
2010;Reimherr et al. 2005;Sobanski et al. 2010;Wender et al. 1981). 
1.3 Comorbidity in adult ADHD 
Adding to the complex questions about persistence of ADHD into adulthood is the 
considerable presence of comorbid disorders throughout the lifespan. A majority of adult 
ADHD patients have one or more comorbid psychiatric disorders (Barkley et al. 2008b;Nutt 
et al. 2007). In terms of diagnosis and treatment there is a rationale to divide the most 
frequently occurring comorbid disorders in adult ADHD into two groups; 1) disorders that are 
congenital or with childhood onset like pervasive developmental disorders (ICD-10 F84), 
learning disabilities (ICD-10 F81), Tourettes syndrome and other tic disorders (ICD-10 F95), 
and disruptive behavior disorders (ICD-10 F91), and 2) common psychiatric disorders like 
affective disorders (ICD-10 F30-39), anxiety disorders (ICD-10 F40-43) , personality 
disorders (PD) (ICD-10 F60) and substance use disorders (SUD) (ICD-10 F10-19). There are 
gender differences in the comorbidity pattern in adult ADHD that reflects gender differences 
in the general population; more anxiety, depression, eating disorders and borderline 
personality disorder in women, and more SUD and antisocial personality disorder (ASPD) in 
men (Biederman et al. 1994;Biederman et al. 2004;Halmoy et al. 2009;Rasmussen and 
Levander 2009;Rucklidge 2008;Sobanski et al. 2007;Sprafkin et al. 2007). 
Despite the high numbers of comorbid disorders in adult ADHD the rates may not be 
elevated beyond the rates seen in other clinical control groups (Barkley et al. 2008b), and 
research indicate that only dysthymia, alcohol abuse disorder, SUD, and antisocial behavior 
disorders like oppositional defiant disorder (ODD), conduct disorder (CD) and ASPD, are 
specifically linked to ADHD (Barkley et al. 2008b). SUD and antisocial behavior disorders 
are related to a severe course of ADHD (Mannuzza et al. 1998;Thapar et al. 2006). A number 
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of studies have showed a robust relationship between the occurrence of ADHD, ASPD and 
SUD (Barkley et al. 1990;Biederman et al. 1997;Katusic et al. 2005;Mannuzza et al. 
1991;McGough et al. 2005). 
1.3.1 Comorbid Substance Use Disorders 
SUD is characterized by a pattern of continued pathological use of legal and/or illegal 
substances. This pathological use results in adverse social consequences, such as failure to 
meet work, family, or school obligations, or legal problems. DSM-IV distinguishes between 
the substance dependence and abuse by defining substance dependence in terms of 
physiological and behavioral symptoms of substance use, and substance abuse in terms of the 
social consequences of substance use. 
Studies in samples of adult ADHD patients have showed high prevalence’s of SUD, 
but the estimates are varying. A population study from the US found that 15.2% of adults with 
ADHD had a SUD, compared with 5.6% of people without ADHD (Kessler et al. 2006). 
Several studies have shown evidence indicating an overlap between ADHD and SUD that is 
bidirectional and larger than expected by chance (Wilens et al. 2005a). In clinical samples of 
adult ADHD with high levels of comorbid disorders the prevalence of comorbid SUD may 
range between 35 and 55 % (Wilens et al. 2005a). Conversely, in clinically referred and 
epidemiologically derived groups of substance abusing adolescents and adults the prevalence 
of ADHD is between 40 and 75 % (Wilens et al. 2005a). The co-occurrence between ADHD 
and SUD may partially be mediated by comorbid bipolar disorder and antisocial behavior 
disorders such as ODD, CD and ASPD (Flory et al. 2011;Harty et al. 2011;Kollins 
2008;Mannuzza et al. 2008;McGough et al. 2005), but ADHD by itself is probably a 
significant risk factor for SUD (Biederman et al. 1995;Kousha et al. 2012). Studies have 
shown that the mean onset of SUD is approximately three years earlier for adolescents with 
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ADHD compared to control groups (Wilens et al. 1997). Patients with SUD and comorbid 
ADHD have a more prolonged SUD, and the remission time is considerably longer, compared 
to SUD patients without ADHD (Kollins 2008).  
Clinical assessment of SUD may be challenging because the symptoms of acute and 
chronic drug intake and abstinence can resemble other medical or psychiatric symptoms like 
agitation, hallucinations, restlessness, communication difficulties or psychosis (Schuckit 
2006). The clinician can fail to ask about alcohol and substance use (Hansen et al. 2000), and 
it may be underreported by the patients (de Beaurepaire et al. 2007). Studies of on-site urine 
screening tests for substances in urine have shown a large risk for inaccuracy (Bagoien et al. 
2009;Mordal et al. 2010). Among psychiatric patients, when moderate or high prevalence of 
substance use is suspected, chromatographic methods for testing substances in urine should be 
considered for screening (Mordal et al. 2010). 
A few studies have shown a possible protective effect of early CS treatment against 
the development of SUD in adulthood (Barkley et al. 2003;Biederman 2003;Katusic et al. 
2005;Wilens et al. 2003), but the findings are not robust and there is a need for more research. 
A small number of controlled studies on CS treatment in adult ADHD with comorbid current 
SUD have shown no or very limited effect on both the ADHD symptoms and the SUD 
(Carpentier et al. 2005;Levin et al. 2006;Levin et al. 2007;Schubiner et al. 2002;Wilens et al. 
2005b). 
 
 
 
 
19 
 
1.3.2 Comorbid Antisocial Personality Disorder 
ASPD is according to DSM-IV an Axis II personality disorder characterized by a pervasive 
pattern of disregard for, and violation of, the rights of others that begins in childhood or early 
adolescence and continues into adulthood. Epidemiological studies have shown that 40-70% of 
children with ADHD meet the criteria for oppositional defiant disorder (ODD) and/or conduct 
disorder (CD) (Maughan et al. 2004;Szatmari et al. 1989). In groups of children with ODD 
and/or CD 40-60% meets the criteria for ADHD (Maughan et al. 2004;Szatmari et al. 1989). 
According to the ICD-10 system these children are often diagnosed with F90.1 hyperkinetic 
conduct disorder. It is important to emphasize that ADHD and CD are distinct psychiatric 
conditions, and that one can distinguish between these conditions in terms of diagnosis and 
treatment (Newcorn et al. 2009). In young adults disruptive behavior can persist and develop 
into ASPD. The estimate for ASPD in clinical samples of adults with ADHD varies between 7 
and 44% (Barkley et al. 2008b).  
 The ICD-10 diagnosis dissocial personality disorder is corresponding to the DSM-IV 
diagnosis ASPD, but research has shown that the diagnostic criteria are remarkably 
discordant. In a study examining the cross-system concordance between the personality 
disorders of DSM-IV and Diagnostic Criteria for Research of ICD-10 the authors found the 
least concordant pair of personality disorders to be antisocial and dissocial (Ottosson et al. 
2002). The reasons appear to be different criteria formulations and arbitrary thresholds for 
diagnoses, and the criteria for dissocial personality disorder may be vague compared with 
ASPD. Studies have shown a lower diagnostic threshold for ICD-10 to fulfill the criteria for 
personality disorder diagnoses compared to the DSM-IV (Sara et al. 1996;Starcevic et al. 
1997). 
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1.4 Functional impairment in adult ADHD 
ADHD in adults is in several studies associated with poor functional outcome in 
important life domains like educational and occupational achievement (Fischer et al. 
1990;Kessler et al. 2005a;Mannuzza et al. 1993;Mannuzza et al. 1997;Murphy et al. 
2002;Rasmussen and Gillberg 2000).  Severity of childhood ADHD and comorbidity with CD 
is reported to correlate with the poor functional outcome in adults (Barkley et al. 
1990;Newcorn et al. 2004). Other studies have indicated that occupational outcome might be 
more related to ADHD itself when the condition is continuing into adulthood (Mannuzza et al. 
1993).  
ADHD is related to criminality in adults, but research suggests that most of this 
relationship is mediated by comorbid CD and ASPD. Mannuzza and colleagues found in a 
prospective follow-up study that the presence of an antisocial/CD in young adulthood almost 
completely accounted for the increased risk for criminal activities whether or not it was 
accompanied by a SUD. Continuing ADHD at follow-up, by itself, was not associated with 
arrest history (Mannuzza et al. 1989). When the present studies started very few studies had 
addressed the relationship between CS treatment of childhood ADHD and functional 
outcomes in adulthood.
 
1.5 Central Stimulant treatment of ADHD in adults  
ADHD is recognized as a lifelong condition in many patients, and therapy should for 
most individuals be long-term (Greydanus et al. 2007;National Institute for Health and 
Clinical Excellence 2008). A multimodal therapeutic approach is recommended in all ages, 
including behavioral therapy or cognitive behavioral therapy, psycho-education and 
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pharmacotherapy (Haavik et al. 2010;National Institute for Health and Clinical Excellence 
2008). Pharmacological treatment has been the primary treatment for ADHD in adults, 
although a growing number of studies have showed that cognitive behavioral therapy also 
may improve ADHD symptoms in both medicated and not medicated adult ADHD patients 
(Safren et al. 2005;Safren et al. 2010a;Stevenson et al. 2002).  
1.5.1 Central Stimulants 
Central Stimulants (CS) like methylphenidate (MPH) and amphetamine (AMP) are 
considered to be the cornerstone of pharmacological treatment in ADHD. Non-stimulant 
medications like atomoxetine, bupropion, tricyclic antidepressants and guanfacine have also 
showed efficacy in reducing ADHD symptoms, but the effect sizes are probably lower 
compared to CS and there are few studies comparing CS and non-stimulants directly (Faraone 
et al. 2006b;Gibson et al. 2006;Newcorn 2008;Verbeeck et al. 2009;Wilens et al. 2002). 
The calming effect of AMP on hyperactive children was discovered as early as 1937, 
and MPH was introduced as treatment for the same group in the 1960s (Lange et al. 2010). A 
large number of randomized, controlled studies and several meta-analyses have shown good 
short term efficacy of these drugs in all ages (Faraone et al. 2004;Faraone and Glatt 
2009;Koesters et al. 2009;Schachter et al. 2001;Smith et al. 2000). There is some evidence for 
long-term efficacy in children (Jensen 2002;National Institute for Health and Clinical 
Excellence 2004;Wilens et al. 2002). When the present studies were initiated we could not 
find randomized, controlled CS treatment studies of adult ADHD lasting longer than 20 
weeks, and very few long-term naturalistic or open-label extensions of controlled studies. 
Studies on effectiveness variables in CS treatment of adult ADHD were also lacking (Weiss et 
al. 2006). 
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The response rate of CS in adult ADHD is reported to be somewhat lower than in 
children and adolescents, and in controlled trials the response rate to CS in adults range 
between 25 to 78 % (Mattes et al. 1984;Spencer et al. 1996). MPH and AMP have distinct 
pharmacodynamic properties, and patients often express a preference for one preparation over 
another. However, in controlled trials of CS treatment in adult ADHD the efficacy of both 
MPH and AMP are roughly 60 % (Wilens et al. 2011). 
All CS act on the catecholaminergic system and are thought to reduce ADHD 
symptoms by enhancing the availability of dopamine and norepinephrine in parts of the brain 
(Wilens 2008). The last two decades of innovation in the pharmacotherapy of ADHD has 
mostly been related to the development of different forms and release properties of MPH and 
AMP. In contrast to the original immediate release (IR) formulation of MPH, a range of 
different extended release (ER) formulations have been introduced (Banaschewski et al. 
2006). The main argument for introducing these formulations has been the potential for better 
adherence and continuity to the treatment due to the simplified medication regimen when the 
patient only need one daily dose. To our knowledge the validity of this hypothesis had not 
been examined properly when the present study started. 
Among the CS drugs MPH has been most used world-wide to treat ADHD in all ages, 
but the pattern of consumption of different CS varies geographically. A population-based 
prevalence study from the Nordic countries, including Norway, showed that the MPH/AMP 
ratio was more than 20:1 (Zoega et al. 2012) in all age groups. A retrospective claims-based 
analysis of a managed care population in USA showed a MPH/AMP ratio near 50:50 in all 
ages together, and a ratio of almost 2:3 in adult ADHD patients (Christensen et al. 2010).  
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1.5.2 Effectiveness versus efficacy 
In medicine effectiveness relates to how well a treatment works in clinical practice, as 
opposed to efficacy, which measures how well it works in well-controlled clinical trials or 
laboratory studies. In terms of CS treatment of adult ADHD several clinically important 
effectiveness variables were understudied when the present studies started. Examples of such 
variables were rates of discontinuation of CS treatment in ordinary clinical practice, predictors 
for continuity and reasons for discontinuation of CS treatment, and the impact of comorbid 
disorders on aspects of CS treatment (Peterson et al. 2008;Weiss et al. 2006). In spite of good 
short-term efficacy in controlled studies there was evidence from more longitudinal studies of 
early discontinuation and short duration of CS treatment in many adult patients (Aanonsen 
NO 2004;Biederman et al. 2005;Olfson et al. 2007;Perwien et al. 2004;Weiss et al. 2006). 
Research indicates that the rate of discontinuation is especially large in the crucial 
developmental stage of late adolescence (McCarthy et al. 2009). Lack of efficacy and not 
tolerable adverse effects are common reasons for discontinuation of CS treatment but cannot 
alone explain the large discontinuation rates in clinical and community based studies. In a 
chronic and often life-long condition like ADHD one must expect prolonged CS treatment to 
be necessary to improve symptoms and reduce functional impairment.  
2. The present thesis 
From 1997 CS treatment of adult patients with ADHD was permitted by the 
Norwegian Health Authorities. Until then ADHD in adults was an almost unknown condition 
in Norwegian adult psychiatry. The lack of experience and knowledge about diagnosing and 
treating the disorder in adults raised numerous questions for the clinicians. The diagnostic 
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process was complicated and challenging partly due to high rates of comorbid disorders, 
requiring meticulous differential diagnostic assessments. Further there were challenges in 
relation to the pharmacological treatment of adult ADHD. CS is classified as narcotics and the 
use of these drugs was controversial in the public and among health care providers. It was 
known from research performed in the US that CS treatment of ADHD patients with 
comorbid SUD was associated with an increased risk for misuse, abuse and diversion of the 
drugs (Wilens et al. 2006).  
Despite many unanswered questions and several controversial issues most clinicians 
soon realized that this was a severely impaired group of patients with high levels of functional 
impairment. In light of the suffering of the patients and all the unresolved questions a need to 
systematize our clinical experiences emerged. At this time the scientific knowledge about 
adult ADHD was almost entirely based on US studies.  Norwegian or Scandinavian studies on 
the topic were almost lacking. This gave me the idea to initiate a research project; ADHD in 
adults - background, comorbidity and course of treatment, based on a naturalistic and 
retrospective methodological approach using medical records as the source of data. As will be 
described later (Material and methods; Patients; Diagnostic assessment) the Norwegian 
Health Authorities established in 1997 a system of Expert Committee of Hyperkinetic 
Disorders/ADHD and mandatory procedures for assessment of adult ADHD. Due to this 
system large amounts of semi structured data was collected and documented in the medical 
records. The project had two main aims; 1) describe the clinical characteristics, functional 
impairment and comorbidity in this newly recognized group of patients in Norwegian adult 
psychiatry, and 2) investigate the course of long-term CS treatment in adult ADHD by 
variables like CS treatment duration, predictors of long-term CS treatment and impact of 
comorbidity on CS treatment.  
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At the same time another research project was initiated; ADHD in adults: The clinical 
significance of symptoms, functional impairment and quality of life. An aim of this study 
was to explore the relationship between CS treatment in childhood and adult occupational 
outcome. 
 
2.1 Research questions 
To describe psychiatric comorbidity and functional impairment in 3 samples of 
clinical adult ADHD patients (Paper I-IV)  
To investigate CS treatment in a sample of adult ADHD and identify variables 
predicting long-term (> 3 years) CS treatment (Paper II) 
To investigate the prevalence of SUD during long-term CS treatment in a sample of 
adult ADHD and identify variables associated with SUD during treatment (Paper III)  
To identify variables predicting occupational outcome in adult ADHD (Paper IV) 
2.2 Materials and methods 
The present study is based on a retrospective, naturalistic design of 3 samples of adults 
diagnosed with ADHD in North-Trøndelag County in the period 1997 to 2009 using data 
collected from medical records. Paper IV additionally includes a cross-sectional 
questionnaire.  
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2.2.1 Patients  
2.2.1.1 Recruitment of patients to the present studies 
Papers I-III include nearly complete samples of adult ADHD patients consecutively 
diagnosed and treated with CS from the catchment area of Levanger hospital (90.000 
inhabitants) during two partially overlapping time intervals; Paper I includes patients from 
1997 to 2003 (N=45). Paper II and III extend inclusions from 1997 to May 2005 (N=117). 
The 45 patients in Paper I are included in the second sample. The Ministry of Health and Care 
Services gave permission for one psychiatrist (the author) to read the medical records and 
collect the data.  The patients were informed by postal mail about the study and given the 
opportunity not to participate. Two patients refused participation. 
The sample in Paper IV are based on invitations to participate sent by postal mail to all 
patients in the catchment areas of Levanger and Namsos hospitals being diagnosed with adult 
ADHD in the period 1997 to 2009. The hospitals have a total catchment area of 130.000 
inhabitants, living in small towns and rural districts in Nord-Trøndelag County in Norway.  
During the period 586 adult patients had been diagnosed with Hyperkinetic disorder/ADHD 
according to the Patient Administrative System. A preliminary assessment showed that 79 of 
the subjects had been incorrectly registered with the diagnosis, 30 patients were found not to 
have a valid diagnosis, and 6 persons had died. A final number of 471 patients were invited to 
participate in the study. The response rate was 31.6 % (152 patients). Three patients were 
excluded due to specific learning difficulties, and the final number of participants in Paper IV 
was 149. 
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2.2.1.2 Diagnostic assessment 
In the period 1997 to May 2005 the assessment of adult ADHD patients in Norway 
was done in two steps.  
In the first step the primary assessment was done according to procedures published 
by Expert Committees of Hyperkinetic Disorders/ADHD (Attachment I), as part of ordinary 
hospital routines. The Expert Committees of Hyperkinetic Disorders/ADHD were established 
by the Norwegian Health Authorities in 1997 to secure adequate diagnosing and treatment of 
adult ADHD patients. In the period from October 1997 to May 2005 all patients with ADHD 
over 18 years who were considered for treatment with CS had to be evaluated and approved 
by one of three committees. During these years the committees handled more than 5000 
applications for treatment, recommending CS treatment in 3397 cases. In May 2005 this 
system was replaced by National Guidelines for Diagnosing Lifespan ADHD (The Norwegian 
Directorate of Health 2004). These guidelines continued the assessment procedures 
introduced by the Expert Committees. Levanger and Namsos hospitals implemented these 
guidelines, and introduced two additional elements; 1) the General Adult ADD Symptom 
Checklist (GAASC) (Amen 1997) was replaced by the Adult ADHD Self-Report Scale 
(ASRS) Version 1.1 (Kessler et al. 2005b), and 2) the Mini-International Neuropsychiatric 
Interview (MINI) (Sheehan et al. 1998) was introduced as a mandatory tool for diagnosing 
comorbidity.  
The procedures included a systematic assessment of ADHD according to the ICD-10, 
research criteria (World Health Organization 1992) (Attachment II), with two modifications: 
The inattentive subtype of ADHD according to DSM-IV was regarded as sufficient for the 
diagnosis, and the presence of comorbid psychiatric disorders were not a criterion for 
exclusion regarding neither the diagnosis of ADHD nor CS treatment. The procedures 
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included an examination for prior or present symptoms of psychosis, depression, bipolar 
disorder, anxiety disorders, conduct disorders and SUD. A physical examination, blood tests 
and electrocardiogram were mandatory. Collateral information about the patients’ childhood 
(<7 years old) were collected from parents, teachers or other relevant persons to confirm 
whether they met criteria for ADHD in childhood. The patients also had to complete two self-
report inventories; the Symptom Checklist 90-items (SCL-90) (DeRogatis et al. 1974) and the 
GAASC. When comorbid SUD was suspected the patients were required to substantiate at 
least 3 months of abstinence from SUD before initiating CS treatment, and in many cases also 
a period after initiation of treatment. Abstinence was in most cases documented by the use of 
urine tests twice weekly at the office of the general practitioner, and analyzed by using Liquid 
Chromatography/Mass Spectrometry methodology.  
In a second step a report with all information gathered in the first step was sent to the 
Expert Committee of Hyperkinetic Disorders/ADHD for a definitive recommendation. The 
clinicians in charge of the treatment would start CS treatment only after a written 
recommendation was received from the Committee.  
2.2.2 Measures
2.2.2.1 Sociodemographic variables 
In Papers I-III sociodemographic data like age, gender, level of education and 
occupational status at the time of data collection were collected from the medical records. In 
Paper IV this information were obtained from the participants using a self-report 
questionnaire. Occupational status refers to the individual’s source of income. The Norwegian 
social welfare system comprises social benefits such as unemployment benefit, sickness 
benefits, vocational rehabilitation, and medical rehabilitation. Due to their temporary nature, 
these categories are statistically pooled in one group, called temporary social benefit. 
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Disability pension differs from temporary social benefits as it is most often a lifelong benefit 
obtained only when treatment and rehabilitation most likely will not enable the individual to 
attain a job again.
In Paper IV we also wanted to measure the extent of labor force participation, and 
included in the self-report questionnaire an item about the number of months the patient had 
been in work for the last year. 
  2.2.2.2 Comorbidity 
Comorbidity with psychiatric disorders was based on information collected from the 
medical records. A comorbid disorder was diagnosed if the medical record clearly confirmed 
the criteria of a diagnosis according to DSM-IV (Papers II-IV) or ICD-10 Diagnostic criteria 
for research (Paper I). In Paper III patients with lifetime comorbid SUD were classified as 
Comorbid SUD. The group Comorbid SUD was sub-classified into 4 groups according to the 
main substance of abuse; alcohol, amphetamine, opiates and cannabis. Patients with no 
lifetime history of SUD were classified as No comorbid SUD. 
2.2.2.3 Prevalence of SUD during CS treatment  
In Paper III clinical data about SUD during the CS treatment period was collected 
from the medical records. Relapse or onset of SUD was defined as fulfilling the DSM-IV 
criteria for one or more of the sub-classes of SUD for at least a week (alcohol, amphetamines, 
cannabis and opiates).  Patients with one or more relapses were classified into the group 
Relapse of SUD, while patients without relapse were classified into the group No relapse of 
SUD. Patients without previous comorbid SUD, but with onset of SUD during CS treatment, 
would be classified as Onset of SUD group. 
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2.2.2.4 Duration of abstinence from SUD
The duration of abstinence from SUD before CS treatment was estimated based on all 
available information in the medical records at baseline. The patients were divided into two 
groups according to the DSM-IV remission specifiers (American Psychiatric Association 
1994).  
1) Remission < 12 months.  
 Early Partial Remission: This classification indicates that one or more, but not all 
criteria for Dependence or Abuse have been met for at least one month, but less than 12 
months. 
Early Full Remission: This classification indicates that no criteria for Dependence or 
Abuse have been met for at least one month, but for less than 12 months. 
2) Remission > 12 months.  
Sustained Partial Remission: This classification indicates that one or more, but not all 
criteria for Dependence or Abuse have been met for a period of 12 months or longer. 
Sustained Full Remission: This classification indicates that none of the criteria for 
Dependence or Abuse have been met at any time during a period of 12 months or 
longer.  
2.2.2.5 CS treatment variables   
 
Information about received CS treatment was collected at follow-up December 31, 
 
 2008. The total duration of CS treatment was defined as the total number of months the 
 
patients had used CS during the period 1997 to follow-up, as described in the medical 
 
 record. Treatment interruptions that lasted more than 3 months were not included in the total  
 
duration.  In Paper II treatment duration was dichotomized into two groups; patients with 
 
duration of CS treatment less than 36 months or duration of CS treatment 36 months or 
 
more. The types of CS used by the patients were MPH IR, MPH ER (Ritalin LA MPH 
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hydrochloride extended-release capsules or OROS MPH hydrochloride) and dexamphetamine 
 
IR. Amphetamine/dexamphetamine ER was not used because it was not available in Norway 
 
during the study period. The maintenance dose was registered for MPH only. Reasons for 
 
discontinuation of CS treatment was registered, and so was the number of patients switching 
 
to a second type of CS and the type of the second CS. 
 
2.2.2.6 Self-Report Questionnaire
The questionnaire included sociodemographic characteristics like gender, age, current 
level of education, occupational status, and number of months in ordinary work the last year. 
Occupational status refers to the individual’s source of income (Attachment 4). The 
questionnaire further included the ASRS-version 1.1. The ASRS is the WHOs self-report 
rating scale for adult ADHD) and is designed to assess current ADHD symptoms. It consists 
of 18 items based on the DSM-IV diagnostic criteria for ADHD. The items are measured on a 
5-point scale with range 0 to 72. Higher scores indicate higher frequencies of symptoms and 
symptom load. The scale is organized in two sections, each with its own sum score. Items 1 to 
9 (Part A) reflects symptoms of inattention and items 10 to 18 (Part B) reflects symptoms of 
impulsivity or hyperactivity. 
 
2.2.3 Procedures  
The majority of data for the present study was retrospectively collected from the 
medical records by an experienced psychiatrist (the author).  The Ministry of Health and Care 
Services gave permission only for one psychiatrist to read the medical records and collect the 
data. A data collecting form was made before screening the medical records (Attachment 3). 
Baseline was set to the time the patient started CS treatment in the period 1997 to 2003 (Paper 
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I) and May 2005 (Paper II and III). For paper II and III the time for follow up was December 
31, 2008; 43 months after the inclusion of the last patient in May 2005. Many patients 
terminated the CS treatment before December 31, 2008. For these patients follow-up was the 
time of their last contact with the hospital. For Paper IV the cross-sectional data from the 
questionnaire (Attachment 2) was completed by the patients in the summer of 2009, and the 
retrospective data from the medical records collected autumn 2009. 
 
2.3 Statistics 
Data were initially analyzed to describe and compare frequencies and prevalence of 
variables. We used contingency tables (Chi-square tests and Fisher’s exact test) for 
categorical variables, and Students T-test and Mann-Whitney tests for continuous variables. In 
Paper II and III logistic regression analyses were carried out to explore possible effects of 
different variables on dichotome outcome measures. Odds ratio for the significant predictive 
variables was calculated. In Paper IV we conducted bivariate correlation analyses to explore 
correlations between possible predictor variables. To test the model with the hypothesized 
predictors we used a hierarchical multiple regression model.  
The statistical analyses were performed using the SPSS (Statistical Package for the 
Social Sciences, SPSS Inc, Chicago, IL, USA) version 12 (Paper I), version 17 (Paper II and 
III), and  version 16 (Paper IV). 
2.4 Ethics 
In the period 1997 to May 2005 the patients had provided a written general consent 
when they started CS treatment allowing data from their medical records to be used in later 
research projects initiated by health authorities. For Paper I the Levanger Hospital and the 
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Regional Research Ethical Committee of Middle Norway gave permission to collect data 
from the medical records without an additional consent from the patients. 
 For Paper II and III the Ministry of Health and Care Services gave permission to 
collect data from the medical records without an additional consent from the patients, but all 
patients had to be informed by postal mail about the study and given the opportunity not to 
participate. The Regional Research Ethical Committee of Middle Norway and the Levanger 
Hospital approved the study.
For Paper IV the study had been approved by the Norwegian University of 
Technology and science, Faculty of Social science, Department of Psychology and Levanger 
Hospital, and the Regional Ethical Committee of Middle Norway. Apart from the exceptions 
described above with respect to the lack of informed consent the studies have been carried out 
in accordance with the Declaration of Helsinki.
 
3. Results 
3.1 Paper I 
Paper I is a naturalistic, retrospective study using data from medical records.  The aim 
of the study were to explore the clinical characteristics, functional impairment and 
comorbidity of a sample consisting of all patients diagnosed with adult ADHD and starting 
CS treatment in a specific catchment area during the period 1997 to 2003 (N=45; 11 females 
and 34 males). The patients were evaluated when they started CS treatment in adulthood. 
Mean age was 28.3 years (males 29.4, females 25.1). Forty-four patients (97.8%) fulfilled the 
criteria for DSM-IV ADHD combined type in childhood. All described a chronic course of 
ADHD symptoms from childhood to adulthood. Twenty- nine (62.2%) had been in contact 
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with child and adolescence psychiatry (CAP) and/or pedagogic-psychological services (PPS) 
at school (22 men, 7 women), but only 8 (17.8%) had been diagnosed with ADHD in 
childhood or adolescence. Nine (20%) had been diagnosed with learning disability, 15 (33%) 
with CD and four (8.9%) had epilepsy in childhood. Seven patients (15.5 %), all men, had 
been medicated with CS in childhood for shorter periods (maximum 2 years).  
Fourteen patients (31.2 %) were employed or studying. Most patients (78 %) were 
receiving their income from social welfare benefits. Twenty-one (46.7 %) patients had one or 
more criminal sentences.  
Thirty-nine patients (86.7 %) had at least one life-time comorbid disorder according to 
ICD-10 Criteria for research. Lifetime major depression (53.0 %), dyssocial personality 
disorder (44.0 %), alcohol abuse disorder (47.0 %), cannabis abuse disorder (51.0 %) and 
amphetamine abuse disorder (49.0 %) were the most frequent comorbid diagnoses. There 
were no significant differences between men and women. 
 
3.2 Paper II 
Paper II is a naturalistic, retrospective study using data from medical records. The aim 
of the study were to examine duration of CS treatment and identifying predictors for long-
term treatment (> 3 years) in a sample of almost all patients diagnosed with adult ADHD and 
starting CS treatment in the period 1997 to May 2005 (N=117; 32 females and 85 males). 
Almost all patients (96.7 %) fulfilled the criteria for DSM-IV ADHD combined subtype in 
childhood. All described a chronic course of ADHD symptoms from childhood to adulthood. 
22 patients (18.8%) had been diagnosed with ADHD in childhood or adolescence, and 17 
patients (14.5 %) had been medicated with CS before age 18. Mean age was 28.6 years (males 
28.1, females 30.1). 
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Lifetime depression (32.5 %), ASPD (29.9 %), alcohol abuse disorder (47.0 %), 
cannabis abuse disorder (41.9 %), amphetamine abuse disorder (41.0 %) and Any SUD (46.2 
%) were the most common comorbid DSM-IV disorders. The variable Any SUD includes 
amphetamines, cannabis, and/or opiates. There were significant gender differences, with 
significantly more ASPD (p= 0.003) and Any SUD (p=0.047) among the men, and borderline 
personality disorder (p=0.001) among the women. Level of educational achievement was very 
low, and only 21 patients (17.9 %) were employed or studying.   
Most patients (94.0 %) started treatment with MPH IR, but 52.1 % changed later to 
MPH ER (54.1 %) or dexamphetamine IR (45.9 %). The main reasons for changing to a 
second CS were side effects (29.5 %), lack of effect (23.0 %), compliance problems (21.3 %) 
and problems related to SUD (6.5 %). The average maintenance dose of MPH IR and/or ER 
was 58.9 mg/day. The median duration of CS treatment at follow-up was 33.0 months.  
In univariate analyses patients with CS treatment duration 36 months were 
significantly more often treated with MPH ER, had significantly more often switched to a 
second CS, a higher maintenance dose of MPH, and lower prevalence of the adverse effect 
nervousness. They had significantly less contact with pedagogical and psychological services 
(PPS) in school, and more comorbidity with SUD and ASPD.  A logistic regression analysis 
of this seven variables with p<0.05, and the variable gender, found that use of MPH ER 
(p=0.009) was a positive predictor of CS treatment duration 36 months, and comorbid ASPD 
(p=0.005) was a negative predictor of CS treatment duration 36 months  
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3.3 Paper III 
Paper III is a naturalistic, retrospective study using data from medical records. The aim 
of the study were to examine the prevalence and predictors of SUD during CS treatment in a 
sample of almost all patients diagnosed with adult ADHD and starting CS treatment in the 
period 1997 to May 2005 (N=117; 85 males and 32 females). The sample is identical to the 
sample in Paper II. 
The Comorbid SUD group (N=65) indicating lifetime history of SUD (alcohol, 
amphetamine, cannabis and/or opiates) before CS treatment had one or more relapses of SUD 
in 38 patients (58.5 %) during the CS treatment period. The No comorbid SUD group (N=52) 
had no incidence of SUD during CS treatment.  
Univariate analyses showed that the Relapse of SUD group (N=38) had significantly 
more comorbid ASPD [27 patients (71.1 %) versus 7 patients (25.9 %), p<0.001], younger 
age when starting CS treatment as adults (26.9 versus 31.6 years, p<0.001), and fewer patients 
with a length of cannabis abstinence more than 12 months before initiation of CS treatment [3 
patients (7.9 %) versus 7 patients (25.9 %), p=0.003], compared to the No relapse of SUD 
group. The logistic regression analysis with the 3 significant variables as independent 
variables showed that length of cannabis abstinence more than 12 months was a significant 
(p=0.012) negative predictor for relapse of SUD.
The Relapse of SUD group had significantly reduced length of CS treatment compared 
to the No relapse of SUD group (19.3 versus 40.0 months, p= 0.001). The duration of CS 
treatment was almost equal in the No relapse of SUD group and the No comorbid SUD group 
(40.0 versus 41.1 months). Twenty-seven (71.0 %) patients in the Relapse of SUD group 
terminated CS treatment because of a relapse of SUD.  
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3.4 Paper IV 
Paper IV is a cross-sectional study using data collected from two different sources; the 
medical records and a self-report questionnaire. The aims of the study were to describe 
functional and clinical characteristics, and to identify possible predictors of occupational 
outcome in a clinical sample of adult ADHD invited to participate (N=149; 78 females, 71 
males).   
Twenty-three patients (17.4%) had started CS treatment by the age of 18 or earlier, 45 
patients (34.1%) had started between the age of 19 and 30, 40 patients (30.3%) had started 
between the age of 31 and 40, and 24 patients (18.2%) had started by the age of 41 or above.  
Lifetime depression (37.8 %), lifetime anxiety disorder (14.6 %), ASPD (9.0 %), 
alcohol abuse disorder (23.3 %), and SUD (28.1 %) were the most common comorbid DSM-
IV disorders. We found significantly more SUD and ASPD among the men. 
Forty-eight patients (33.3%) were receiving disability pension and 55 patients (38.2%) 
were received some type of temporary social benefit. Fifty-two patients (44.4%) had not been 
in work or studies for the last 12 months, 18 (15.4%) had been working or studying for 1 to 4 
months, 9 (7.7%) for 5 to 8 months, and 38 (32.5%) for 9 to 12 months.  
Age of first CS treatment was significantly and negatively related to occupational 
status, r = í.24 (p < .05). ASRS scores were also negatively related to occupational status, 
with a significant negative correlation between Part A (inattentiveness) and occupational 
status, r = í.20 (p < .05). 
Hierarchical regression was applied to test the hypothesis of predictors of occupational 
outcome. Later age of first CS treatment and higher inattentiveness ratings were associated 
with lower level of employment.
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4. Discussion 
4.1 Methodological issues 
The present study has a number of strengths: we were able to include almost all adult 
ADHD patients consecutively starting CS treatment in the catchment area; the assessment of 
the ADHD diagnosis was rigorous for a naturalistic study with developmental history 
obtained from collateral informants in most cases; and the duration of follow-up was long 
(minimum 43 months). These characteristics of the samples in Paper I-III make the present 
study quite unique in the research literature of adult ADHD. Despite these strengths the study 
has limitations, and some of the limitations are inherent in the naturalistic and retrospective 
study design.
4.1.1 Patients 
The patients in the present samples consist of predominantly untreated, self-referred 
adults with ADHD, as opposed to children with ADHD followed to adulthood (Barkley et al. 
2008a). The mean age (28.3 and 28.6 years) and the female/male ratio (25/75) in the samples 
in Paper I-III was almost the same (mean age 28.3, female/male ratio 27/73) as found in 
another Norwegian study by Rasmussen and Levander (Rasmussen and Levander 2009) 
describing a sample of 600 consecutive adult ADHD patients from Middle and Northern 
Norway. The large proportion of males and the low mean age distinguishes the present studies 
from the majority of randomized, controlled studies of CS treatment. A meta-analysis of 22 
controlled studies of pharmacological treatment in adult ADHD found a female/male ratio of 
41/59, with a mean age of 38 years (Peterson et al. 2008). The mean age (33.7 years) and the 
female/male ratio (52/48) in the present sample of invited patients (Paper IV) are more in 
accordance with the results from this review. The sample described in Paper IV is also similar 
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to the sample in another Norwegian study of 414 adult ADHD patients invited to participate, 
showing a mean age of 34.5 years and a female/male ratio of 48/52 (Halmoy et al. 2009). A 
German study of 70 adult ADHD patients recruited from consecutive referrals to an ADHD 
specialty outpatient clinic showed a mean age of 36.8 years and a female/male ratio of 46/54 
(Sobanski et al. 2007). Kooij and colleagues found an under representation of men and 
younger people in their validity study from Netherlands (Kooij et al. 2005). These findings 
may reflect a greater willingness among females and older people to participate in studies. A 
major strength of the present study is the clinical representativeness and especially the 
inclusion of young men. Data from this kind of naturalistic sample may give important 
information that supplements the results from controlled studies of CS treatment in adult 
ADHD.  
While most randomized, controlled studies of CS treatment in adult ADHD exclude 
patients with comorbid disorders typical for clinical settings, the present study includes almost 
all patients consecutively diagnosed with ADHD and initiating CS treatment in the catchment 
area. An objection against the high rates of comorbid disorders in a study like the present is 
the problem with generalization of the results to samples with less comorbidity. Despite the 
lack of exclusion criteria in the present study there are many sources of bias associated with 
the referral procedure (Hartman et al 2002). During the first years of this study the knowledge 
about adult ADHD was sparse and variable in the Norwegian health care system, among the 
patients and in the community. General practitioners referral practices for assessment of adult 
ADHD was probably inconsistent. Patients with serious and ongoing comorbidity may never 
have reached the point in their health care process where assessment for ADHD was 
considered. Selection biases are probably present to a lesser degree in the samples in Paper I-
III than in the invited sample in Paper IV. Patients responding to an invitation to participate in 
a research project tend to be more motivated and concerned about their health, and may differ 
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from the broader target population with respect to gender, age, comorbidity, etc. (Hartman et 
al 2002).  
 
 
4.1.2 Procedures  
The present data are based on the clinical contact between patient and clinician as 
described in the medical record thus providing an image of a real world situation. In addition 
the majority of patients were followed for years and in most cases the clinician knew the 
patient well.  
However, the naturalistic and retrospective approach of the present study provides 
several limitations. Retrospective collection of data from medical records gives variable 
amounts and quality of information from one patient to another. The quality of the data 
depends on a number of factors like frequency of contact between patient and clinician, and 
quality and amount of documentation in the medical record. Information about 
sociodemographic data and educational and occupational status is likely to be reliable. The 
assessment of comorbidity, length of abstinence from SUD and prevalence of relapse of SUD 
during CS treatment may be less reliable. Information about CS treatment given is likely to be 
reliable despite we had no other control of the patient’s adherence to the prescribed treatment 
than prescriptions registered and information from the patient. The Ministry of Health and 
Care Services gave permission for only one psychiatrist to read the medical records and 
collect the data, and this restriction made it impossible to use more than one investigator and 
calculate inter-rater reliability.  
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The patients were diagnosed and treated by several clinicians with heterogeneous 
experience and competence. This problem was to some extent compensated for by using 
procedures published by the Expert Committee of Hyperkinetic Disorders/ADHD and a 
reassessment of all cases by the committee (Paper I-III). The total assessment of the patients 
in this sample may be considered as comprehensive. 
In Paper III the detection of relapse or onset of SUD during CS treatment was an 
important issue. The clinician treating the patient used in most cases urine tests analyzed by 
chromatographic methods if SUD was suspected and the patient did not reveal such use. 
Studies done among patients admitted to Norwegian acute psychiatric wards have shown that 
SUD is under detected if the clinician uses interview as the only source of information (Flovig 
et al. 2009;Mordal et al. 2010).  However, negative urine tests do not exclude current SUD as 
the different toxicological techniques have different sensitivity, specificity and analytic range. 
In urine most drugs can be detected only a few days after intake. Cannabis can be detected for 
a longer period (Verstraete 2004). The high level of baseline comorbid SUD and the high 
number of detected relapses of SUD could suggest that the routines for diagnosing and 
detecting SUD at the clinic were adequate.  
According to ICD-10 a diagnosis of ADHD requires the presence of symptoms before 
7 years of age. Although retrospective assessment of psychopathology is non-optimal in 
adults, there are studies indicating that a retrospective diagnosis of childhood-onset ADHD 
can be made reliably (Spencer et al. 1998;Ward et al. 1993). Furthermore the diagnostic 
criteria were verified by corroborative information from persons with knowledge about the 
patients’ childhood in a substantial number of our subjects. However, there are uncertainties 
embedded in the retrospective approach of diagnostic assessment. Acknowledged limitations 
notwithstanding, the knowledge gained from a retrospective and naturalistic study like the 
42 
 
present is relevant as an addition to empirical studies with more stringent methodology, or 
where such are lacking, as is the case concerning the present topics. 
 
 
 
4.2 Discussion on the main findings 
 4.2.1 Comorbidity 
The prevalence of comorbid disorders was high in the present studies. In Paper I we 
found that 87 % of the patients had at least one comorbid psychiatric disorder, and this is in 
line with other studies (Barkley et al. 2008b;McGough et al. 2005).The prevalence’s of the 
most frequent comorbid disorders showed substantial variation between the 3 samples; 
lifetime major depression ranged between 33 and 53 %, ASPD between 9 and 44 %, alcohol 
abuse disorder between 23 and 47 %, and any SUD between 28 and 46 %. A dominant trend 
was that the prevalence’s of ASPD, alcohol abuse disorder and SUD were highest in the 
samples described in Paper I-III, reflecting the inclusion of all patients in the catchment area 
and the high proportion of young males. Research has consistently showed that the rates of 
CD, ASPD, alcohol use disorder and SUD are significantly higher for males than females 
(Biederman et al. 1994;Halmoy et al. 2009;Sobanski et al. 2007;Sprafkin et al. 2007). 
Conversely, for lifetime major depression the prevalence was higher among patients included 
in Paper IV than Paper II/III, probably reflecting the high proportion of women in this sample. 
From the literature on ADHD it appears that female patients have more affective disorders 
than males (Biederman et al. 1994;Halmoy et al. 2009;Sobanski et al. 2007;Sprafkin et al. 
2007). However, this is also reflected in the general population. In a large epidemiological 
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study from Norway the lifetime prevalence of major depression in men was 9.9% versus 24% 
among women (Kringlen et al. 2001). 
There were no significant differences between the genders in ADHD symptoms in the 
samples in Paper II-IV, but the females had significantly higher levels of psychiatric 
symptoms as measured by SCL-90 Global Severity Index, and this is in line with previous 
research (Biederman et al. 1994;Cumyn et al. 2009;Rasmussen and Levander 2009;Robison et 
al. 2008).  
Compared to previous studies following children with ADHD to adulthood (Mannuzza 
et al. 1993;Mannuzza et al. 1998;Weiss et al. 1985) the comorbidity rates of the samples in 
the present Papers I-III are high. The prevalence rates of ASPD, alcohol use disorder and 
SUD are more like previous studies of self-referred adults with ADHD (Biederman et al. 
1993;Murphy and Barkley 1996). More recently published clinical samples of self-referred 
adult ADHD patients from Norway and Germany present comorbidity rates lower than the 
present study (Halmoy et al. 2009;Rasmussen and Levander 2009;Sobanski et al. 2007). 
There may be several reasons for the high comorbidity rates in the present study. Research 
has showed that comorbidity is significantly higher in clinical samples like the present 
compared to community and epidemiological samples (Kessler et al. 2006). Secondly the 
samples consisted of patients assessed not only at the psychiatric clinic but also at a 
specialized out-patient clinic for SUD and a clinic for congenital neuropsychiatric disorders. 
A third reason may be the method of collecting data from the medical records. The medical 
records contained for most patients abundant information collected during several years of 
treatment and from various sources.  Compared to a cross-sectional interview or self-rating 
inventory the detection rate of comorbid disorders may be higher with this methodology. 
Previous research has showed that the combined subtype of ADHD is related to functional 
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impairment and comorbidity (Molina et al. 2009), and in our samples the combined subtype 
dominated.  
Barkley and colleagues compared in their book “ADHD in adults. What the science 
says” a sample of children with ADHD followed to adulthood with a sample of self-referred 
adults with ADHD. The results indicated that children with ADHD as adults had more 
comorbid SUD and ASPD compared with self-referred adults, but less anxiety and depression 
(Barkley et al. 2008b). The present samples cannot exactly be classified into one of these 
groups; the majority of the patients were self-referred as adults, but a substantial number was 
first diagnosed with ADHD as children, or was identified as children with mental problems in 
child and adolescence psychiatry. 
The prevalence of dissocial personality disorder according to ICD-10 Criteria for 
research in Paper I was twice as high as reported for DSM-IV ASPD in most other studies 
(Mannuzza et al. 1993;Mannuzza et al. 1998). Further, the prevalence for dissocial personality 
disorder was higher in Paper I than the prevalence for ASPD presented in Paper II-IV. This 
may be due to the lack of concordance between the criteria for the two diagnoses (Ottosson et 
al. 2002;Sara et al. 1996;Starcevic et al. 1997). Another reason may be the small numbers in 
Paper I which may cause large effects on prevalence. The relationship between ADHD 
combined type and ASPD is consistent with findings from previous studies on children and 
adults (Murphy et al. 2002). The very high prevalence of dissocial personality disorder in 
Paper I may reflect a genuine high level of this disorder among the ADHD patients seeking 
CS treatment the first years after CS treatment was allowed for adults in 1997. 
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4.2.2 Functional impairment 
Many previous studies have shown significant educational and occupational 
impairment in samples of adult ADHD (Biederman et al. 1993;Mannuzza et al. 1993;Murphy 
and Barkley 1996;Murphy et al. 2002;Rasmussen and Gillberg 2000), and even worse in the 
presence of comorbid psychiatric disorders (Jensen et al. 1997;Sobanski et al. 2007). The 
present samples of predominantly self-referred adults with ADHD had a very high degree of 
educational and occupational impairment. The rate of current employment ranged between 16 
and 22 %, in contrast to the overall employment rate in the general adult population in 
Norway which is about 70 % (Statistics Norway 2005). These findings may indicate that our 
sample is more impaired than is typical of most US studies (Barkley et al. 2008d), but major 
differences in the social welfare system between the countries may explain lower employment 
figures in patient populations in Norway as compared to the US. The number of patients 
having junior high school as their highest degree of education ranged between 48 % in Paper 
IV to 80 % in Paper I-III, as compared to 30 % in the general Norwegian population in 2009 
(Statistics Norway 2010). Thus a majority of the sample had an educational level not suited 
for most domains in the labor-market. In Paper IV only 8.9 % reported having a college or 
university degree, compared to 20.8 % in the general Norwegian population at the time of 
data collection (Statistics Norway 2010).  
Barkley and colleagues (Barkley et al. 2008d) have compared samples of self-referred 
adults with ADHD to children with ADHD growing up and showed that the latter group is 
more adversely affected in their educational career. This may seem like a contradiction to our 
findings of very impaired self-referred adults with ADHD. A possible explanation is that the 
self-referred adults assessed for ADHD in Norway the first years after CS was allowed in 
1997 probably are more severely affected by their ADHD than is typical of US studies 
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(Barkley et al. 2008d). Previous findings also suggest that unemployment might be related to 
other symptoms, deficits and comorbid disorders than what is accounted for by ADHD alone 
(Sobanski et al. 2007;Young et al. 2003). 
One might speculate that the severe impairment seen in our samples in terms of 
educational and occupational functioning could be due to lack of proper recognition and 
treatment in childhood ADHD. The design of the present study does not allow for any 
conclusions regarding this question. There are, however, some arguments for this view. 
Alcohol use disorders and SUD are by themselves unfavourable indices for functional 
impairment. ADHD is a risk factor for drug abuse (Biederman et al. 1997;Mannuzza et al. 
1991), and recent studies indicate that CS treatment in childhood may reduce the risk for later 
adult SUD, especially in adolescence but also in adulthood (Biederman et al. 2008a;Wilens et 
al. 2003). There are many theories why CS treatment reduces the risk for SUD, and one is that 
CS indirectly reduces the risk by diminishing conduct symptoms, as CD and later ASPD are 
predictors of SUD (Klein et al. 1997). Another possible explanation is that CS treatment 
reduces ADHD symptoms, demoralization, poor self-esteem, academic and occupational 
failure; factors associated independently with risk for SUD (Brook et al. 1995;Crum et al. 
1992;Kandel and Logan 1984). A review by Hechtman and Greenfield (Hechtman and 
Greenfield 2003) found that children treated with CS for 2 years showed improvement in 
ADHD symptoms, comorbid ODD, and academic and school functioning. Follow-up periods 
into adulthood showed that CS treatment in childhood also was beneficial for social skills and 
self-esteem. Higher doses and longer treatment period predicted less comorbidity and better 
social functioning (Hechtman and Greenfield 2003). A Norwegian study by Halmøy and 
colleagues found that early recognition and treatment of ADHD was a strong predictor of 
being in work as an adult, independently of comorbidity, substance abuse, and current 
treatment (Halmoy et al. 2009).  
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An issue related both to ASPD and functional impairment is criminality. In Paper I we 
showed that half of the patients (47 %) had one or more criminal sentences, and 24 % had at 
least 2 types of sentences (violence, theft, drug-related crime and drunk driving). A 
substantial number of studies have shown that ADHD is a predictor for criminal activity itself, 
although comorbidity with CD and ASPD is the major cause of criminality in the ADHD 
population (Barkley et al. 2008c). 
 
 
4.2.3 Variables predicting long-term (> 3 years) CS treatment 
The primary aim of Paper II was to investigate the duration of CS treatment in a 
naturalistic and unselected sample of highly comorbid self-referred adults with ADHD. 
Despite the high levels of comorbidity and functional impairment the patients had a median 
duration of CS treatment of 33.0 months. This is comparable to an Italian study of CS 
treatment in children showing 46 % persistent use after 36 months (Atzori et al. 2009). We 
have found no other studies of adult ADHD showing duration of CS treatment as long as the 
present study. A systematic long-term follow-up study from Sweden showed that 50% of the 
patients continued CS treatment for 24 months or more (Bejerot et al. 2010). This study had 
excluded patients with major comorbidities like SUD and severe personality disorders. A 
report to Norwegian Health authorities on all adult ADHD patients treated with CS in Norway 
in the period 1997–2003 (1328 patients), showed that only 20% were still in treatment after 
24 months (Aanonsen NO 2004). In an open study of treatment with mixed amphetamine salts 
(MAS) in a selected US sample of adult ADHD patients, only 34 % of the patients were still 
using MAS after 24 months (Biederman et al. 2005). Studies of US pharmacy claim data 
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bases show duration of CS treatment for only a few months in adult ADHD (Hodgkins et al. 
2011;Olfson et al. 2007).  
The reasons for the long duration of CS treatment in the present sample are unknown. 
The hospital had a policy of following the patients a long time before transferring the 
responsibility for treatment to the general practitioner. These circumstances, and the fact that 
the clinic was the only psychiatric clinic diagnosing and treating ADHD in the area, may have 
resulted in more stable and prolonged contact between the clinician and the patient. Results 
from the MTA study have indicated that treatment by specialists in ADHD treatment give 
better results than community treatment in children and adolescents (Molina et al. 2009). 
Olfson and colleagues also showed an association between longer duration and treatment by a 
psychiatrist (Olfson et al. 2007). In addition, the population in the catchment area, which is 
made up of rural districts and small towns, is quite homogeneous and stable. This could 
contribute to longer duration of treatment, although research has revealed conflicting results 
about the significance of urban versus rural districts on duration of CS treatment (Cox et al. 
2003).  
A number of studies from different countries have shown large geographical 
differences in prevalence of CS treatment in both children and adults with ADHD, without 
having been able to identify the causes of these geographical variations (Aanonsen NO 
2004;Cox et al. 2003;Janols et al. 2009;Prosser and Reid 2009). Nord-Trøndelag county, were 
the present study took place, are among the counties in Norway with the highest prevalence of 
CS treatment in Norway (The Norwegian Institute of Public Health 2010). Bejerot and 
colleagues (Bejerot et al. 2010) discusses the importance of skillful, understanding and 
supportive clinicians to achieve high compliance rates. Other authors have discussed the 
importance of enthusiastic physicians for CS treatment prevalence and duration (Cox et al. 
2003).  
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Another major finding in the present study is the positive prediction of CS treatment 
duration 36 months by the use of MPH ER in a severely impaired and comorbid sample like 
the present. This finding adds to other studies indicating an association between ER 
formulations and longer duration of CS treatment in adult ADHD (Kemner and Lage 
2006;Olfson et al. 2007;van den Ban et al. 2010). A Spanish study based on chart reviews also 
found that a switch from MPH IR to MPH ER was associated with both a significant 
reduction of ADHD symptoms, longer treatment duration and better compliance (Ramos-
Quiroga et al. 2008). There is reason to believe that superiority in efficacy and more 
convenient medication of ER formulations may contribute to longer duration and better 
compliance. However, two recent meta-analyses have given conflicting results about the 
superiority in efficacy of ER formulations over IR formulations in controlled studies (Faraone 
and Glatt 2009;Peterson et al. 2008). 
Comorbid ASPD predicted CS treatment duration negatively, and there are several 
possible explanations for this finding. ASPD has a strong association to SUD, and 
information from the medical records revealed that problems related to SUD were important 
reasons for discontinuation of CS treatment in Paper II (23.1 %). In Table 2 of Paper II we 
showed that comorbid Any SUD (includes amphetamine, cannabis and/or opiates), comorbid 
cannabis abuse and comorbid opiate abuse were significantly more prevalent in the group 
with less than 3 years of treatment. However, when entered into the logistic regression model 
none of the comorbid SUD variables were significant predictors, while ASPD was a 
significant predictor (p=0.001). Based on various data from this study it is still reason to 
believe that comorbid SUD is related to shorter duration of CS treatment. Criminal activity, 
which is often associated to ASPD, is also difficult to combine with stable medical follow-up.  
The finding that contact with PPS in school predicted long duration negatively is of 
uncertain importance. At the time the patients in the present study were children, the interest 
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in and knowledge of ADHD was sparse in Norway. Most likely contact with PPS in school 
reflects severity of the condition in childhood, and comorbidity with conduct disorders and 
learning disabilities. 
 The present study showed that it is possible to treat adult ADHD patients with high 
levels of comorbidity and functional impairment for many years. Because of the 
methodological deficiences of the study we could not show improvement in ADHD 
symptoms, comorbidity, quality of life or functional outcomes. A key issue regarding duration 
of CS treatment in adult ADHD is whether the efficacy shown in short-term studies is 
maintained during long-term treatment. In other words; do we know that long-term CS 
treatment is necessary and desirable in adult ADHD? A few long-term studies in children of 
functional outcomes indicates sustained effects of CS treatment on ADHD symptoms over 
years, and even some effect on functional outcomes (Biederman et al. 2009;Hechtman et al. 
1984;Hechtman and Greenfield 2003;Powers et al. 2008). The MTA study showed initially 
that 14 months of intensive CS treatment in a large sample of ADHD children was superior to 
behavioral treatment and community treatment (The MTA Cooperative Group 1999), but later 
follow-up studies of this sample showed that type or intensity of the 14 months treatment did 
not predict functioning 6 to 8 years later (Molina et al. 2009). Instead they found that early 
ADHD symptoms regardless of treatment type was prognostic, and that children with the 
combined subtype of ADHD exhibited significant impairment in adolescence regardless of 
treatment (Molina et al. 2009).  
Very few studies of CS treatment in adult ADHD have lasted more than a year. A 
naturalistic Swedish study showed that 50 % of adult ADHD patients remained in CS 
treatment after 2 years, and the effect on ADHD symptoms was good and the adverse effects 
mild (Bejerot et al. 2010). Biederman and colleagues found similar results in an open-label 
24-months study of mixed amphetamine salts in adult ADHD, but in this study only 36 % 
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continued treatment for 2 years (Biederman et al. 2005).  In a recently published open-label 
trial by Wender and colleagues, patients continuing 12 months of MPH immediate release 
(IR) treatment showed significant improvement on both symptoms and social functioning 
(Wender et al. 2010). Based on the limited research available we may conclude that CS 
treatment in adult ADHD has long-term beneficial effects for many patients. 
 
4.2.4 Prevalence of SUD during long-term CS treatment  
To our knowledge the present study is the first to explore this clinically important and 
controversial issue. The present study could not detect any onset of SUD during CS treatment 
in the group of patients who did not have comorbid SUD at baseline despite a very long 
treatment period (mean 41.1 months). This finding indicates that CS treatment in adult ADHD 
patients with no previous SUD does not precipitate onset of SUD. The results are in line with 
the Swedish study by Bejerot (Bejerot et al. 2010) on long-term CS treatment in ADHD. Their 
study excluded patients “without obvious drug or alcohol abuse or dependence”, and found 
that only 2 out of 133 patients had to terminate CS treatment because of SUD during a 2 years 
follow-up period. Previous studies have showed that CS treatment in children may reduce the 
risk for SUD in adult life (Wilens et al. 2008). However, some research has indicated that 
initiation of treatment with CS in adolescence and young adults is linked to increased risk of 
poly-drug use and non-medical stimulant use (Kollins 2008). The mean age in the present 
study and in the study by Bejerot (Bejerot et al. 2010) was 28.6 and 31.1 years respectively, 
and this may represent an age group with low risk for debut of SUD.  
The study revealed that among patients with Comorbid SUD at baseline a majority 
(58.5%) had one or more relapses during the CS treatment period. When interpreting these 
results we have to consider that SUD is a chronic relapsing disorder. Present research data 
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indicates that up to 90 % of patients who go into remission from SUD relapse over time 
(Sellman 2010). Compared to the high relapse rate in SUD patients the relapse rate in the 
present group of ADHD patients with Comorbid SUD may not be high. However, the lack of 
a proper control group makes it impossible to conclude about the protective or causative 
effects of CS treatment when it comes to relapse of SUD in adult patients with ADHD and 
comorbid SUD. 
A relapse of SUD during CS treatment is challenging for the treatment of ADHD. 
Previous research have showed no or very sparse effects of CS treatment in controlled studies 
of adult ADHD with current comorbid SUD, both on ADHD symptoms and SUD (Konstenius 
et al. 2010;Wilens 2009). More important than lack of efficacy of the treatment is the possible 
increased risk for health damage when CS treatment is combined with SUD. The NICE 
guidelines recommend CS treatment for adults with ADHD who also misuse substances only 
when the clinician is an appropriately qualified healthcare professional with expertise in 
managing both ADHD and SUD (National Institute for Health and Clinical Excellence 2008). 
CS treatment of ADHD patients with comorbid SUD is associated with an increased risk for 
misuse, abuse and diversion of the CS drugs (Kaloyanides et al. 2007;McCabe et al. 
2006;Wilens et al. 2006). The clinician should take precautions like obtaining urine 
toxicology screens, prescribing long-acting CS drugs or non-stimulant drugs, put more 
emphasis on psychotherapeutic approaches and focus strongly on the importance of taking 
medications regularly (Mariani and Levin 2007;Upadhyaya 2007) 
The decision to terminate CS treatment or not when a patient experience a relapse of 
SUD will be an individual assessment in each case, depending on a number of factors. In the 
present sample 71.1 % of the patients with comorbid SUD had to terminate CS treatment 
because of SUD, and this is an important reason for the significantly reduced treatment length 
in the Relapse of SUD group (19.3 vs. 40.0). The treatment length in the No relapse of SUD 
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group was almost identical with the treatment length in the No comorbid SUD group (40.0 vs. 
41.1).  
4.2.5 Variables predicting relapse of SUD during CS treatment 
The findings in the present study that ASPD are related to relapse of SUD are  not 
surprising, but to our knowledge this has not been documented before in the context of CS 
treatment in adult ADHD with comorbid SUD. Studies from populations of patients with 
SUD have showed that comorbid PD predicts relapse (Thomas et al. 1999). Some studies 
indicate that the increased rates of SUD in populations with ADHD are mostly accounted for 
by the presence of comorbid CD (Harty et al. 2011).  
Previous research in populations with SUD have documented that the risk for relapse 
is highest during the first period after cessation, and more specifically the first 100 days 
(Dekel et al. 2004;Gedaly et al. 2008;Kirshenbaum et al. 2009;Nides et al. 1995;Plebani et al. 
2009). The finding that more than 12 months abstinence from cannabis was a significant 
negative predictor of relapse of SUD may be clinically important, but due to the naturalistic 
approach and small numbers the results must be interpreted with caution. The finding that 
cannabis is stronger related to relapse than the other substances must be further examined in 
larger and more controlled studies and may be due to the small numbers in the present study. 
 
4.2.6 Variables predicting occupational outcome in adult ADHD 
The present study showed that older age when CS treatment was initiated and 
inattentiveness as measured by ASRS was significantly negatively correlated with the degree 
of occupational participation in adulthood, expressed by number of months in work the last 
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year. The regression analysis showed that early CS treatment was a significant positive 
predictor of occupational participation. Recent studies suggest that CS treatment is beneficial 
for adult function in general (Spencer et al. 2008), thus possibly a predictor of occupational 
function. A Norwegian study found that childhood diagnosis and treatment with CS might 
have a beneficial effect on adult occupational outcome as measured by being in work or not 
(Halmoy et al. 2009).  
We also found that ASRS inattentiveness negatively predicted the degree of 
occupational participation. This is in line with a recent study showing that inattention was 
associated with the greatest loss of income and disadvantage in a sample of Australian adult 
ADHD patients (Ebejer et al. 2012). Research has further documented that childhood 
inattention persists to a higher degree into adulthood than hyperactivity/impulsivity (Kessler 
et al. 2010). A study by Mannuzza and colleagues reported a strong relationship between 
number of ADHD symptoms and degree of general impairment, including work functioning 
(Mannuzza et al. 2010). A comprehensive review of follow-up and cross-sectional studies 
concluded that no other identified factor than ADHD alone predicted occupational outcome in 
adults with ADHD (Barkley et al. 2008d). The finding from the present study that symptoms 
of inattentiveness predict occupational participation adds to these results. Contrary to what 
has been reported in some previous studies (Halmoy et al. 2009;Sobanski et al. 2007) we 
found no effect from comorbidity on occupational participation, and our findings are more in 
line with those of Barkley and colleagues (Barkley et al. 2008d).  
Compared with age- and gender-matched controls ADHD in adults is associated with 
occupational under attainment relative to what may be expected according to their intellectual 
potentials (Biederman et al. 2008b). A large-scale prevalence study among workers showed 
that ADHD was significantly associated with decrements in both quantitative and qualitative 
role performance in work (de et al. 2008). Compared with other workers those with ADHD 
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had more days out of work-role, being less productive, and having reduced work performance 
quality (de Graaf et al. 2008). Cross-sectional studies have shown lower occupational 
functioning in adults with ADHD compared with controls (Barkley et al. 2008d). This 
indicates that the symptoms of ADHD play an important role in occupational functioning. 
This is supported by a recent study reporting associations between the severity of ADHD 
symptoms and work impairment (Safren et al. 2010b). Being in work seems to include the 
ability to perform several skills and strategies relevant to most functional domains. Executive 
function deficits such as problems with self-management of time, self-motivation, and self-
discipline are found to contribute to occupational problems in adults (Barkley and Murphy 
2010).  
5. Conclusions 
-Adults with ADHD had far lower levels of education and employment compared to the 
general population. 
-Adults with ADHD had high levels of psychiatric comorbidity, especially alcohol and 
substance use disorders and antisocial personality disorder 
-Most adults with ADHD received treatment with central stimulants for several years, and 
treatment duration for more than 3 years was predicted positively by the use of extended 
release formulations of methylphenidate, and negatively by comorbid antisocial personality 
disorder 
-In adult ADHD without comorbid substance use disorder central stimulant treatment does not 
precipitate new onset of substance abuse, and in adults ADHD with substance use disorder the 
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relapse rate is not higher than in substance use disorder alone during central stimulant 
treatment 
- Later age of first central stimulant treatment and higher inattentiveness ratings were 
associated with lower level of employment in adulthood 
6. Future perspectives 
The present thesis emphasizes the high rates of comorbidity between adult ADHD and 
other psychiatric disorders like SUD and ASPD. Despite a fair amount of research on the 
nature of the relationship between these disorders there are still many unanswered questions 
concerning issues like shared etiology and genetics, prevalence, and the importance of 
comorbidity on treatment of adult ADHD. The possibility that the triad consisting of ADHD, 
SUD and ASPD constitutes a separate entity with specific etiologic and clinical characteristics 
must be explored further. This question is even more relevant when DSM-V in 2013 probably 
rejects the use of the 3 subgroups introduced in DSM-IV. In an even longer perspective the 
designation ADHD may be replaced by new designations with stronger scientific and 
biological basis. 
In addition to a further emphasis on the impact of comorbidity on the course of ADHD 
future research should explore the functional impairment following ADHD in all ages, and 
identify treatment which is capable of reducing impairment. 
Further research should also focus on the treatment providing systems and investigate 
factors that could enhance CS treatment effectiveness such as adherence and compliance.  
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The relationship between duration of CS treatment in adulthood and improvement in 
symptoms and functional impairment should be investigated in studies with more controlled 
design. 
A longer period of abstinence from SUD before CS treatment may reduce the risk for 
relapse. However, trial derived evidence is lacking and it needs to be examined in a study 
with a prospective, controlled design.   
Early detection and treatment of ADHD is shown in the present and some other long-
term studies to have a positive effect with regards to adult functional impairment. However, 
most long-term studies are open-label extensions or naturalistic studies, with several 
methodological limitations. Efforts should be made to initiate larger, scientifically more 
stringent and multisite naturalistic studies to investigate the impact of different treatments on 
adult functional outcomes. 
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Attachment I  
Procedures published by Expert Committees of Hyperkinetic Disorders/ADHD  

  
 
 
Attachment II 

 The International Classification of Disease, 10th revision, research criteria  
 
Hyperkinetisk forstyrrelse – ICD-10 forskningskriteriene 
 
Diagnosen krever klare tegn på sviktende oppmerksomhet, unormalt aktivitetsnivå 
og rastløshet som forekommer på tvers av situasjoner og som vedvarer 
over tid, og som ikke er forårsaket av noen annen lidelse som for eksempel 
autisme og affektive lidelser. 
 
G1. Svikt i oppmerksomhet. Minst seks av symptomene på sviktende oppmerksomhet 
må ha vedvart i minst 6 måneder, og i en grad som hindrer adekvat 
tilpasning, og som ikke er aldersadekvat. 
(1) er ofte ikke oppmerksom på detaljer, eller gjør feil på grunn av skjødesløshet, 
i skolearbeid, arbeid, eller i andre aktiviteter 
(2) klarer ofte ikke å fokusere oppmerksomhet over tid i forhold til arbeidsoppgaver 
eller lek 
(3) hører ofte tilsynelatende ikke på hva som blir sagt til ham/henne 
(4) klarer ofte ikke å følge instrukser eller å gjøre ferdig skolearbeid eller 
arbeidsoppgaver (ikke på grunn av uvilje eller manglende forståelse av 
instruksjon) 
(5) har ofte vansker med å organisere oppgaver og aktiviteter 
(6) prøver ofte å unngå, eller misliker sterkt, oppgaver som for eksempel 
hjemmelekser som krever vedvarende konsentrasjon 
(7) roter ofte bort eller mister ting som er nødvendig for visse aktiviteter som 
hjemmelekser, for eksempel blyanter, bøker, leker eller verktøy 
(8) blir lett distrahert av ytre stimuli 
(9) er ofte glemsom gjennom daglige aktiviteter 
  
G2. Hyperaktivitet. Minst tre av symptomene på hyperaktivitet må ha vært til 
stede i minst 6 måneder, og i en grad som hindrer normal tilpasning og som 
ikke er aldersadekvat. 
(1) er ofte rastløs med hender eller føtter eller vrir seg i stolen 
(2) forlater plassen sin i klasserommet eller i andre situasjoner hvor det er 
forventet at han/hun skal sitte stille 
(3) løper ofte omkring eller klatrer rundt i situasjoner hvor det ikke er passende 
(hos ungdom og voksne finnes kanskje bare en følelse av rastløshet) 
(4) er ofte unødig støyende under lek eller har vanskeligheter med å involvere 
seg stille i fritidsaktiviteter 
(5) viser vedvarende økt motorisk aktivitet som ikke i særlig grad lar seg 
modifisere av sosial sammenheng eller krav. 
 
G3. Impulsivitet. Minst ett av symptomene har vedvart gjennom minst 6 måneder, 
og i en grad som hindrer normal tilpasning og som ikke er aldersadekvat. 
(1) buser ut med svaret før spørsmålet er ferdigstilt 
(2) mestrer dårlig å stå i kø eller vente på tur i lek/spill eller gruppesituasjoner 
(3) avbryter eller forstyrrer andre (for eksempel bryter inn i andres samtaler 
eller lek) 
(4) snakker ofte ustoppelig uten å ta hensyn til sosiale begrensninger. 
 
G4. Plagene skal ha startet før fylte 7 år. 
 
G5. Utbredt. Kriteria bør være oppfylt i mer enn enkelt situasjon, for eksempel 
bør kombinasjon av uoppmerksomhet og hyperaktivitet viser seg både hjemme 
og på skolen, eller både på skolen og i en annen situasjon hvor vedkommende 
blir observert, for eksempel i klinikken. (Holdepunkter for utbredthet 
må vanligvis komme fra flere kilder; foreldres utsagn om klasseromatferd vil 
for eksempel neppe være tilstrekkelig). 
 
G6. Symptomene under G1-G3 forårsaker betydelige plager eller svekkelse i 
sosial, utdannings- eller yrkesmessig funksjon. 
 
G7. Tilstanden fyller ikke kriteria for gjennomgripende utviklingsforstyrrelse 
(F84.-), manisk episode (F30.-), depressiv episode (F32.-) eller angstlidelse 
(F41.-) 
 
 
 
 
 
 
 
 
 
 
 
 
 Attachment III 
Data collecting form for screening of medical records  

  
Versjon 16.01.09 
 
Variabler: ADHD hos voksne; forløpsstudien   
 
 
1.0 Demografiske data: 
 
1.1 Kjønn        Mann 0         Kvinne 1 
1.2 Punkt 3.5 Alder ved inklusjon (behandlingsstart med sentralstimulerende  
medikamenter (SSM))    _____ 
 
2.0 Bakgrunnsdata fra før fylte 18 år: 
2.1 Kontakt  Pedag.-Psykol. Tjeneste (PPT)  0  1  
2.2 Kontakt Barne- og ungdomspsykiatri (BUP)  0  1 
  
2.3 Diagnoser fra BUP 
ADHD      0  1 
Atferdsforstyrrelse    0  1 
Lærevansker     0  1 
Annet __________________   0  1 
  
2.4 Behandling i BUP 
SSM      0  1  
Hvis ja; 
Hvilket medikament    ____________ 
Alder ved behandlingsstart   ____________ 
Varighet (måneder)    ____________ 
 
2.5 Negative livshendelser i barndom (<18 år): 
 Dødsfall nær slektning/venn   0  1 
 Alvorlig somatisk sykdom (egen)   0  1 
  Alvorlig ulykke/brann (selvopplevd)  0  1 
 Forårsake alvorlig skade/død   0  1 
 Utsatt for vold utenfor hjemmet   0  1 
 Utsatt for vold i hjemmet    0  1 
 Psykisk sykdom hos foreldre   0  1 
 Rusmisbruk hos foreldre    0  1  
 Utsatt for seksuelt overgrep   0  1 
 Alvorlig/langvarig mobbing   0  1 
 Opplevd foreldres skilsmisse   0  1 
 Barnevernstiltak     0  1 
 Fosterhjemsplassert    0  1 
 Adoptert     0  1 
 Annet_____________________   0  1 
 Sumscore     ____ 
 
2.6 Livstidsforekomst allergi, atopi, astma  0  1  
Hvis ja, hvilken:  Allergi   0  1 
   Atopi   0  1 
   Astma   0  1 
 
3.0 Kontakt med Voksenpsykiatri (VOP) før behandling med SSM 
3.1 Alder første kontakt med VOP (år) _____ 
3.2       Tidspunkt (år)_______________ 
3.3 Alder ADHD diagnose i VOP  _____ 
3.4       Tidspunkt (år)_______________ 
3.5 Alder oppstart SSM i VOP  _____ 
3.6       Tidspunkt (år)_______________  
3.7 Varighet fra første kontakt VOP til ADHD diagnose (mndr)_________    
       
 Henvist til ADHD-utredning fra: 
3.8 I VOP før ADHD-utredning   0  1 
3.9 Overført fra BUP     0  1 
 3.10 Henvist fra fastlege    0  1  
3.11 Henvist fra andre_________________   0  1 
 Psykiatrisk behandling i VOP før ADHD-utredning 
3.12 Poliklin. konsultasjoner (antall)   ______  
3.13 Innleggelser (uker)    ______   
 
 ICD-10 diagnoser satt i VOP før ADHD-diagnose (PAS-koder/benevnelser) 
3.2.1 Psykisk utviklingshemming     0  1 
3.2.2 Alvorlighetsgrad      __________ 
 Læringsforstyrrelser 
3.2.3 Leseforstyrrelser       0  1 
3.2.4 Regneforstyrrelse      0  1 
3.2.5 Skriveforstyrrelse      0  1 
3.2.6 Uspesifiserte lærevansker      0  1 
 Gjennomgripende utviklingsforstyrrelser 
3.2.7 Autisme         
3.2.8 Aspergers syndrom      0  1 
3.2.9 Tourette syndrom      0  1 
  
Substansbrukslidelser 
3.2.10 Alkoholavhengighet/misbruk     0  1 
3.2.11 Amfetaminavhengighet/misbruk     0  1 
3.2.12 Cannabisavhengighet/misbruk     0  1 
3.2.13 Opiatavhengighet/misbruk     0  1 
3.2.14 Sedativa-, hypnotika- og anxiolytikaavh/misbruk   0  1 
3.2.15 Blandingsavhengighet      0  1 
 Stemningslidelser 
3.2.16 Alvorlig depressiv episode, aktuell     0  1 
3.2.17 Alvorlig depressiv episode, tidligere    0  1 
3.2.18 Alvorlig depressiv episode, tilbakevendende   0  1 
3.2.19 Bipolar lidelse, aktuell      0  1 
 3.2.20 Bipolar lidelse type I      0  1 
3.2.21 Bipolar lidelse type II      0  1 
 Angstlidelser 
3.2.22 Panikklidelse       0  1 
3.2.23 Sosial fobi       0  1 
3.2.24 OCD        0  1 
3.2.25 PTSD        0  1 
3.2.26 GAD        0  1 
 Personlighetsforstyrrelser 
3.2.27 Antisosial       0  1 
3.2.28 Ustabil        0  1 
3.2.29 Unngående       0  1 
3.2.30 Avhengig       0  1 
3.2.31 Spiseforstyrrelser      0  1 
3.2.32 Andre psykiatriske lidelser__________________   0  1 
 
4.0 Utredning av ADHD før behandlingsstart 
4.1 Journalinformasjon 
Antall løpende journalsider     _______________ 
4.2 Utredet hvor? 
 Psykiatrisk poliklinikk      0  1 
 Habiliteringstjenesten.      0  1 
 Ruspoliklinikk       0  1 
 Psykiatrisk sengepost      0  1 
 Annet ___________________     0  1 
 
 
 
4.3 F90.0 Hyperkinetisk forstyrrelse; forskningskriteriene 
 ADHD kombinert type      1 
 ADHD hovedsakelig Oppmerksomhetssvikt    2 
 ADHD hovedsakelig Hyperaktivitet-Impulsivitet   3 
  
4.4 Strukturert klinisk intervju: 
 SPIFA       0  1 
 MINI       0  1 
 SCID       0  1 
 
4.5 Nevropsykologisk undersøkelse 
WAIS       0  1 
Utvidet testbatteri     0  1 
 
4.6 Cerebral CT/MR ____________    0  1 
 Normale funn      0  1 
 
4.7 EEG  ________________   0  1 
 Normale funn      0  1 
 
4.8 Blodprøver      0  1 
 Normale funn      0  1 
 
4.9 Komparentopplysninger     0  1 
Hvem_________________________ 
 
4.10 MMPI       0  1 
  
5.0 Funksjonsnivå ved behandlingsstart 
 
5.1 Sivilstatus 
Ugift         0 
Samboende        1 
Gift         2 
Separert        3 
Skilt         4 
 Enke/enkemann        5 
 
5.2 Bosituasjon 
Bor alene        0 
Bor sammen med foreldre      1 
Bor sammen med bare barn      2 
Bor sammen med ektefelle/samboer (og evt barn)    3  
 Bor sammen med andre       4 
5.3 Barn 
Har ikke barn        0 
Har egne barn, men andre har omsorgen     1 
Har omsorg for egne barn (<18 år)      2 
 
5.4 Utdanning 
 Ikke fullført grunnskole       0 
Fullført grunnskole       1 
Fullført videregående skole      2 
Fullført universitet eller høgskole      3 
 
5.5 Arbeid/sysselsetting 
Lever av sosial stønad       0  
 Uførepensjon        1 
Rehabiliteringspenger        2 
Sykemeldt         3 
Yrkesrettet attføring       4 
Arbeidsledighetstrygd       5 
Under ordinær utdanning       6   
 I lønnet arbeid        7 
 
5.6 Kriminalitet før behandling (domfelt): 
Vold                        0  1 
Vinning                       0  1 
 Narkotika                       0  1 
 Promilledom      0  1 
 
6.0 Komorbiditet etter DSM-IV vurdert ved behandlingsstart med SSM 
(Oppfyllelse av diagnosekriteriene klart dokumentert i journal) 
 Ingen sikker komorbiditet      0  1 
 Hvis 0, hvilke diagnoser 
6.1 Psykisk utviklingshemming     0  1 
6.2 Alvorlighetsgrad      __________ 
 Læringsforstyrrelser 
6.3 Leseforstyrrelser       0  1 
6.4 Regneforstyrrelse      0  1 
6.5 Skriveforstyrrelse      0  1 
6.6 Uspesifiserte lærevansker      0  1 
6.7 Atferdslidelse       0  1 
6.8 Trasslidelse       0  1 
 Gjennomgripende utviklingsforstyrrelser 
6.9 Autisme             0  1 
6.10 Aspergers syndrom      0  1 
6.11 Tourette syndrom      0  1 
 Substansbrukslidelser    PÅGA TDR TFR VDR VFR 
6.12 Alkoholavhengighet/misbruk  0 1 0 1 2 3 4 
6.13 Amfetaminavhengighet/misbruk  0 1 0 1 2 3 4 
6.14 Cannabisavhengighet/misbruk  0 1 0 1 2 3 4 
6.15 Opiatavhengighet/misbruk  0 1 0 1 2 3 4 
6.16 Sedativa-, hypnotika- og anx  0 1 0 1 2 3 4 
6.17 Blandingsavhengighet   0 1 0 1 2 3 4 
 
 Forløpsspesifikasjon ved oppstart sentralstimulerende medikamenter 
 Pågående    PÅGÅ 
 Tidlig delvis remisjon   1<TDR<12 måneder 
  Tidlig full remisjon   1<TFR<12 måneder 
 Vedvarende delvis remisjon  12<VDR 
 Vedvarende full remisjon  12<VFR  
 
 Stemningslidelser 
6.18 Alvorlig depressiv episode, aktuell     0  1 
6.19 Alvorlig depressiv episode, tidligere    0  1  
6.20 Alvorlig depressiv episode, tilbakevendende   0  1 
6.21 Bipolar lidelse, aktuell      0  1 
6.22 Bipolar lidelse, tidligere      0  1 
6.23 Bipolar lidelse type I      0  1 
6.24 Bipolar lidelse type II      0  1 
 Angstlidelser 
6.25 Panikklidelse       0  1 
6.26 Sosial fobi       0  1 
6.27 OCD        0  1 
6.28 PTSD        0  1 
6.29 GAD        0  1 
 Personlighetsforstyrrelser 
6.30 Antisosial       0  1 
6.31 Ustabil        0  1 
6.32 Unngående       0  1 
6.33 Avhengig       0  1 
6.34  Spiseforstyrrelser      0  1 
6.35 Andre psykiatriske lidelser__________________   0  1 
 Andre tilstander beskrevet i journal 
6.36 Muskel- og skjelettplager ina     0  1 
6.37 Søvnforstyrrelser ina      0  1 
 
7.0 Symptomnivå ved behandlingsstart 
7.1 SCL-90       0 1 
 7.2 GSI       _______ 
7.3 Hyperkinetisk sjekkliste      0 1 
7.4 HS Score      _______ 
7.5.1 ASRS       0 1 Del A___Del B____ 
 
8.0 Medikamentell behandling (SSM) 
 
8.1 Førstevalg 
 Metylfendidat IR (Ritalin tabletter)    0  1  
Metylfendidat SR (Concerta/Ritalin SR)   0  1 
Amfetamin IR      0  1 
Annet________      0  1       
 
8.2 Maksimal dose      ______ 
8.3 Vedlikeholdsdose     ______ 
8.4 Skifte av sentralstimulerende medikament   0  1 
Fra Metylfenidat til Deksamfetamin   0  1 
Fra Deksamfetamin til Metylfenidat   0  1 
Fra IR til SR (Metylfenidat)    0  1 
Fra SR til IR (Metylfenidat)    0  1 
Begrunnelse for skiftet_______________________________ 
 
8.5 Skiftet skjedde etter (måneder)    ____________ 
8.6 Varighet av ny medikasjon    ____________ 
8.7 Pauser i behandlingen mer enn 3 måneder  ____________ 
8.8 Total behandlingstid med SSM    ____________ 
 
8.9 Registrerte bivirkninger    
Redusert matlyst      0  1 
 Vekttap       0  1 
 Løs mage/diare      0  1 
 Kvalme/uvelhet      0  1 
 Magesmerter      0  1 
  Svimmelhet      0  1 
 Munntørrhet      0  1 
 Tretthet       0  1 
 Nervøs/urolig      0  1 
 Hodepine      0  1 
 Hjertebank/økt puls     0  1 
 Innsovningsproblemer     0  1 
 Søvnproblemer, andre     0  1 
 Irritabilitet      0  1 
 Angst       0  1 
 Depresjonsfølelse     0  1 
 Andre_____________________    0  1 
 
8.10 ”Serious adverse events” under behandling med SSM 0  1 
 Hvis 1, hvilke___________________________________________ 
 
8.11 ”Serious adverse events” etter avsluttet behandling med SSM 
        0  1 
Hvis 1, hvilke___________________________________________ 
 
 
9 Ikke-medikamentell behandling 1. år 
 Hovedbehandlers profesjon 
9.1 Legespesialist     0 
9.2 Psykologspesialist    1 
9.3 Lege      2 
9.4 Psykolog     3 
9.5 Høyskoleutdannet    4 
9.6 Antall polikliniske konsultasjoner   ___________ 
9.7 Innlagt (evt. antall uker_______)   0  1 
9.8 Ansvarsgruppe etablert    0  1 
9.9 Individuell plan     0  1 
  
9 Behandlingseffekt etter 6 uker vurdert fra skjema eller tekst 
10.1 Hyperaktivitet    0 1 2 3 4 
10.2 Impulsivitet    0 1 2 3 4 
10.3 Irritabilitet    0 1 2 3 4 
10.4 Oppmerksomhet    0 1 2 3 4 
10.5 Struktur/organisering   0 1 2 3 4 
10.6 Uro/rastløshet    0 1 2 3 4 
10.7 Distraherbarhet    0 1 2 3 4 
10.8 Annet_______________   0 1 2 3 4 
  
11 Status ved oppfølgingstidspunktet  31.12.2008         
11.1 Total varighet behandlingskontakt VOP (mndr)  _______ 
11.2 Punkt 8.8 Total behandlingstid med SSM   _______ 
 < 3 måneder       0 
 3 måneder-1 år       1 
 1-2 år        2 
 2-3 år        3 
 > 3 år        4 
11.3 Fortsatt medikamentell behandling  0  1 
11.4 Avsluttet medikamentell behandling  0  1 
 
Hvis avsluttet, hvorfor? 
 Pasientens valg pga:    
Bivirkninger      0  1           
Manglende effekt     0  1 
Rusmisbruk     0  1            
Annet      0  1                      
Ukjent årsak      0  1 
 
Behandlers valg pga:    
Bivirkninger      0  1           
Manglende effekt     0  1 
Rusmisbruk     0  1            
Annet      0  1                      
Ukjent årsak      0  1 
 
11.5 Fortsatt behandling i VOP    0  1 
11.6 Overført 1. linje for med. behandling  0  1 
 
11.7 Arbeid/sysselsetting 
 Lever av sosial stønad      0  
 Uførepensjon       1 
Rehabiliteringspenger       2 
Sykemeldt        3 
Yrkesrettet attføring      4 
Arbeidsledighetstrygd      5 
Under ordinær utdanning      6   
 I lønnet arbeid       7 
11.8 Endring i Arbeid/trygdestatus 
 Uendret        0 
 Bedring        1 
 Forverring       2 
 
11.9 Ved tidl. rusmisbruk; tilbakefall   0  1 
 
 
 
 
 Attachment IV 
Self-Report Questionnaire 

  
Spørsmål om behandlingstilbudet du har mottatt ved 
Psykiatrisk klinikk på Sykehuset Levanger: 
Sett ring rundt tallet for det svaret du synes passer best. Kun ett tall for hvert 
spørsmål. 
        
Har det vært viktig for deg å få diagnosen ADHD? 
 
Ikke i det hele tatt  0 
Litt viktig   1 
Ganske viktig   2 
Veldig viktig   3 
 
Hvis du har prøvd medisiner mot din ADHD, synes du at medisinene har vært 
nyttige for deg? 
   
Ikke i det hele tatt  0   
Litt nyttig   1 
Ganske nyttig   2 
Veldig nyttig   3 
 
Hva synes du om det tilbudet Psykiatrisk klinikk gir til voksne pasienter med 
ADHD?  
 
Dårlig    0 
Litt bra    1 
Ganske bra   2 
Veldig bra   3    
 
Hva synes du mangler ved det tilbudet Psykiatrisk klinikk gir til voksne 
pasienter med ADHD? 
Svar: 
 
 Bruker du for tiden medisiner mot din ADHD (Ritalin, dexedrine, concerta, strattera, og 
lignende)? 
0 Nei 
1 Ja 
 
Hvis nei, har du brukt det tidligere og sluttet med det selv? 
      0      Nei  
      1       Ja  
Spørsmål om din nåværende situasjon: 
Sett ring rundt tallet for det svaret du synes passer for deg. Kun ett tall for hvert 
spørsmål. 
Sivilstatus 
0 Jeg er ugift 
1 Jeg er samboende 
2 Jeg er gift 
3 Jeg er separert 
4 Jeg er skilt 
5 Jeg er enke/enkemann 
 
Bosituasjon 
0 Jeg bor alene 
1 Jeg bor sammen med foreldre 
2 Jeg bor sammen med bare barn 
3 Jeg bor sammen med ektefelle/samboer (og evt. barn) 
4 Jeg bor sammen med andre enn de som er nevnt over 
 
Utdanning 
      0       Ikke fullført grunnskole     
      1       Fullført grunnskole      
      2       Fullført videregående skole    
      3       Fullført universitet eller høgskole    
 
Arbeid/sysselsetting 
       0       Lever av sosial stønad     
       1       Uførepensjon      
       2       Rehabiliteringspenger     
       3       Sykemeldt       
        4       Yrkesrettet attføring      
       5       Arbeidsledighetstrygd     
       6       Under ordinær utdanning (ikke attføring)      
       7       I lønnet arbeid      
 
Hva er din nåværende arbeids-/studiesituasjon? 
0 Jeg er skoleelev/student 
1 Jeg er hjemmearbeidende/husmor) 
2 Jeg er i arbeid, ca. 100 % (sett ring rundt selv om du for tiden er sykemeldt) 
3 Jeg er i arbeid, ca. 50 % (sett ring rundt selv om du for tiden er sykemeldt) 
4 Jeg er uføretrygdet 
5 Jeg er arbeidsløs (sett ring rundt selv om du for tiden er under rehabilitering) 
 
Er du for tiden under attføring? 
0 Nei 
1 Ja, ca. 50 % attføring 
2 Ja, ca. 100 % attføring 
3 Ja, annen gradering 
 
Arbeid/studier 
Hvor mange måneder har du arbeidet eller studert minst halv tid (50% eller mer) i løpet av de 
siste 12 måneder? (Regn ikke med tiden du har vært sykemeldt) 
Svar:_____ 
 
 
 
